Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions

Breast cancer (BC) is viewed as a significant public health issue and is the primary cause of cancer-related deaths among women worldwide. Triple-negative breast cancer (TNBC) is a particularly aggressive subtype that predominantly affects young premenopausal women. The tumor suppressor p53 playsa v...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Heliyon Ročník 10; číslo 4; s. e26260
Hlavní autoři: Naeimzadeh, Yasaman, Tajbakhsh, Amir, Fallahi, Jafar
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Elsevier Ltd 29.02.2024
Elsevier
Témata:
breast neoplasms
cancer therapy
Cancer treatment
CRISPR-Cas systems
DNA damage
epidemiology
immunotherapy
Mutant p53
mutants
pathogenesis
premenopause
Prion-like aggregation
public health
Review
Triple-negative breast cancer
Mutant p53
Cancer treatment
Prion-like aggregation
Triple-negative breast cancer
ISSN:2405-8440, 2405-8440
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Breast cancer (BC) is viewed as a significant public health issue and is the primary cause of cancer-related deaths among women worldwide. Triple-negative breast cancer (TNBC) is a particularly aggressive subtype that predominantly affects young premenopausal women. The tumor suppressor p53 playsa vital role in the cellular response to DNA damage, and its loss or mutations are commonly present in many cancers, including BC. Recent evidence suggests that mutant p53 proteins can aggregate and form prion-like structures, which may contribute to the pathogenesis of different types of malignancies, such as BC. This review provides an overview of BC molecular subtypes, the epidemiology of TNBC, and the role of p53 in BC development. We also discuss the potential implications of prion-like aggregation in BC and highlight future research directions. Moreover, a comprehensive analysis of the current therapeutic approaches targeting p53 aggregates in BC treatment is presented. Strategies including small molecules, chaperone inhibitors, immunotherapy, CRISPR-Cas9, and siRNA are discussed, along with their potential benefits and drawbacks. The use of these approaches to inhibit p53 aggregation and degradation represents a promising target for cancer therapy. Future investigations into the efficacy of these approaches against various p53 mutations or binding to non-p53 proteins should be conducted to develop more effective and personalized therapies for BC treatment. The role of Prion-like Behavior of Mutant p53 Proteins in Triple-Negative Breast Cancer Pathogenesis. [Display omitted] •Mutant p53 forms prion-like structures in breast cancer, especially TNBC.•Targeting p53 aggregation is key in TNBC therapy.•Diverse approaches (e.g., chaperone inhibitors, aggrephagy-based approaches, immunotherapy, gene therapy, and CRISPR-Cas9) target p53 aggregates.•Zinc metallochaperones (e.g., ZMC1) and small molecules (e.g., PRIMA-1 and APR-246) show promise in restoring mutant p53 function.
AbstractList Breast cancer (BC) is viewed as a significant public health issue and is the primary cause of cancer-related deaths among women worldwide. Triple-negative breast cancer (TNBC) is a particularly aggressive subtype that predominantly affects young premenopausal women. The tumor suppressor p53 playsa vital role in the cellular response to DNA damage, and its loss or mutations are commonly present in many cancers, including BC. Recent evidence suggests that mutant p53 proteins can aggregate and form prion-like structures, which may contribute to the pathogenesis of different types of malignancies, such as BC. This review provides an overview of BC molecular subtypes, the epidemiology of TNBC, and the role of p53 in BC development. We also discuss the potential implications of prion-like aggregation in BC and highlight future research directions. Moreover, a comprehensive analysis of the current therapeutic approaches targeting p53 aggregates in BC treatment is presented. Strategies including small molecules, chaperone inhibitors, immunotherapy, CRISPR-Cas9, and siRNA are discussed, along with their potential benefits and drawbacks. The use of these approaches to inhibit p53 aggregation and degradation represents a promising target for cancer therapy. Future investigations into the efficacy of these approaches against various p53 mutations or binding to non-p53 proteins should be conducted to develop more effective and personalized therapies for BC treatment.
Breast cancer (BC) is viewed as a significant public health issue and is the primary cause of cancer-related deaths among women worldwide. Triple-negative breast cancer (TNBC) is a particularly aggressive subtype that predominantly affects young premenopausal women. The tumor suppressor p53 playsa vital role in the cellular response to DNA damage, and its loss or mutations are commonly present in many cancers, including BC. Recent evidence suggests that mutant p53 proteins can aggregate and form prion-like structures, which may contribute to the pathogenesis of different types of malignancies, such as BC. This review provides an overview of BC molecular subtypes, the epidemiology of TNBC, and the role of p53 in BC development. We also discuss the potential implications of prion-like aggregation in BC and highlight future research directions. Moreover, a comprehensive analysis of the current therapeutic approaches targeting p53 aggregates in BC treatment is presented. Strategies including small molecules, chaperone inhibitors, immunotherapy, CRISPR-Cas9, and siRNA are discussed, along with their potential benefits and drawbacks. The use of these approaches to inhibit p53 aggregation and degradation represents a promising target for cancer therapy. Future investigations into the efficacy of these approaches against various p53 mutations or binding to non-p53 proteins should be conducted to develop more effective and personalized therapies for BC treatment. The role of Prion-like Behavior of Mutant p53 Proteins in Triple-Negative Breast Cancer Pathogenesis.Image 1 •Mutant p53 forms prion-like structures in breast cancer, especially TNBC.•Targeting p53 aggregation is key in TNBC therapy.•Diverse approaches (e.g., chaperone inhibitors, aggrephagy-based approaches, immunotherapy, gene therapy, and CRISPR-Cas9) target p53 aggregates.•Zinc metallochaperones (e.g., ZMC1) and small molecules (e.g., PRIMA-1 and APR-246) show promise in restoring mutant p53 function.
Breast cancer (BC) is viewed as a significant public health issue and is the primary cause of cancer-related deaths among women worldwide. Triple-negative breast cancer (TNBC) is a particularly aggressive subtype that predominantly affects young premenopausal women. The tumor suppressor p53 playsa vital role in the cellular response to DNA damage, and its loss or mutations are commonly present in many cancers, including BC. Recent evidence suggests that mutant p53 proteins can aggregate and form prion-like structures, which may contribute to the pathogenesis of different types of malignancies, such as BC. This review provides an overview of BC molecular subtypes, the epidemiology of TNBC, and the role of p53 in BC development. We also discuss the potential implications of prion-like aggregation in BC and highlight future research directions. Moreover, a comprehensive analysis of the current therapeutic approaches targeting p53 aggregates in BC treatment is presented. Strategies including small molecules, chaperone inhibitors, immunotherapy, CRISPR-Cas9, and siRNA are discussed, along with their potential benefits and drawbacks. The use of these approaches to inhibit p53 aggregation and degradation represents a promising target for cancer therapy. Future investigations into the efficacy of these approaches against various p53 mutations or binding to non-p53 proteins should be conducted to develop more effective and personalized therapies for BC treatment.Breast cancer (BC) is viewed as a significant public health issue and is the primary cause of cancer-related deaths among women worldwide. Triple-negative breast cancer (TNBC) is a particularly aggressive subtype that predominantly affects young premenopausal women. The tumor suppressor p53 playsa vital role in the cellular response to DNA damage, and its loss or mutations are commonly present in many cancers, including BC. Recent evidence suggests that mutant p53 proteins can aggregate and form prion-like structures, which may contribute to the pathogenesis of different types of malignancies, such as BC. This review provides an overview of BC molecular subtypes, the epidemiology of TNBC, and the role of p53 in BC development. We also discuss the potential implications of prion-like aggregation in BC and highlight future research directions. Moreover, a comprehensive analysis of the current therapeutic approaches targeting p53 aggregates in BC treatment is presented. Strategies including small molecules, chaperone inhibitors, immunotherapy, CRISPR-Cas9, and siRNA are discussed, along with their potential benefits and drawbacks. The use of these approaches to inhibit p53 aggregation and degradation represents a promising target for cancer therapy. Future investigations into the efficacy of these approaches against various p53 mutations or binding to non-p53 proteins should be conducted to develop more effective and personalized therapies for BC treatment.
Breast cancer (BC) is viewed as a significant public health issue and is the primary cause of cancer-related deaths among women worldwide. Triple-negative breast cancer (TNBC) is a particularly aggressive subtype that predominantly affects young premenopausal women. The tumor suppressor p53 playsa vital role in the cellular response to DNA damage, and its loss or mutations are commonly present in many cancers, including BC. Recent evidence suggests that mutant p53 proteins can aggregate and form prion-like structures, which may contribute to the pathogenesis of different types of malignancies, such as BC. This review provides an overview of BC molecular subtypes, the epidemiology of TNBC, and the role of p53 in BC development. We also discuss the potential implications of prion-like aggregation in BC and highlight future research directions. Moreover, a comprehensive analysis of the current therapeutic approaches targeting p53 aggregates in BC treatment is presented. Strategies including small molecules, chaperone inhibitors, immunotherapy, CRISPR-Cas9, and siRNA are discussed, along with their potential benefits and drawbacks. The use of these approaches to inhibit p53 aggregation and degradation represents a promising target for cancer therapy. Future investigations into the efficacy of these approaches against various p53 mutations or binding to non-p53 proteins should be conducted to develop more effective and personalized therapies for BC treatment. The role of Prion-like Behavior of Mutant p53 Proteins in Triple-Negative Breast Cancer Pathogenesis. [Display omitted] •Mutant p53 forms prion-like structures in breast cancer, especially TNBC.•Targeting p53 aggregation is key in TNBC therapy.•Diverse approaches (e.g., chaperone inhibitors, aggrephagy-based approaches, immunotherapy, gene therapy, and CRISPR-Cas9) target p53 aggregates.•Zinc metallochaperones (e.g., ZMC1) and small molecules (e.g., PRIMA-1 and APR-246) show promise in restoring mutant p53 function.
ArticleNumber e26260
Author Tajbakhsh, Amir
Fallahi, Jafar
Naeimzadeh, Yasaman
Author_xml – sequence: 1
  givenname: Yasaman
  surname: Naeimzadeh
  fullname: Naeimzadeh, Yasaman
  organization: Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, 7133654361, Iran
– sequence: 2
  givenname: Amir
  orcidid: 0000-0002-2311-6554
  surname: Tajbakhsh
  fullname: Tajbakhsh, Amir
  email: Tajbakhsh.amir921@gmail.com
  organization: Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
– sequence: 3
  givenname: Jafar
  surname: Fallahi
  fullname: Fallahi, Jafar
  email: jafarf80@gmail.com
  organization: Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, 7133654361, Iran
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38390040$$D View this record in MEDLINE/PubMed
BookMark eNqFUstu1DAUjVARLaWfAPKSTQY_4wQWqKp4VKrEpl1bjnOd8ZCxg-2M1P_hQ_EwQ9WyqWTJln3O8bn3ntfViQ8equotwSuCSfNhs1rD5O6DX1FM-QpoQxv8ojqjHIu65RyfPDqfVhcpbTDGRLRNJ9mr6pS1rMOY47Pq950fIKas_eD8iPIa0Bxd8PXkfgLqYa13LkQULNouBZTRLFhBhAzOJ-Q8ytHNE9QeRp3drlAi6JSR0d5ARLPO6zCCh-TSR3Rb1M0SIxSd8lPUMyzZGZRy1BlGBwkVH8gueYmABhfB5OIlvaleWj0luDju59Xd1y-3V9_rmx_frq8ub2ojGplr3mFpuTaCYNsJjhtOeyIJNpZ0tqe0HWzXcyO54GKg0mI80F4TkIRR0VPJzqvrg-4Q9EaVPmx1vFdBO_X3IsRR6VgMT6AKk2k9aNwA54zKnna9tbhjsizasqL1-aA1L_0WBlNqjnp6Ivr0xbu1GsNOEdy2hMm9m_dHhRh-LZCy2rpkYJq0h7AkxUhLW9nRgn4eKljLJZZtgb577OvB0L9IFIA4AEwMKUWwDxCC1T59aqOO6VP79KlD-grv038847Lez6-U56Zn2cd2QZnvzkFUyTgoGTqkoAzAPaPwB_mu_PU
CitedBy_id crossref_primary_10_1080_15384047_2025_2472432
crossref_primary_10_1016_j_ijbiomac_2025_143883
Cites_doi 10.1126/science.1068537
10.18632/oncotarget.7363
10.1016/j.trecan.2019.11.004
10.1002/bip.22772
10.1016/0092-8674(91)90384-B
10.1056/NEJM199202133260704
10.3389/fonc.2015.00097
10.1038/nchembio850
10.1016/j.bbapap.2017.02.014
10.1016/j.ccell.2015.12.002
10.1038/nrclinonc.2017.151
10.1007/s00280-018-3701-x
10.21037/atm.2016.12.40
10.18632/oncotarget.13475
10.48095/ccko2021382
10.1073/pnas.222406899
10.1073/pnas.1700308114
10.3389/fonc.2020.607149
10.1124/mol.115.097550err
10.1016/j.str.2009.11.011
10.3389/fonc.2015.00288
10.1016/j.isci.2020.102000
10.1016/j.bbcan.2021.188556
10.21873/cgp.20156
10.1038/sj.onc.1208419
10.1097/00004347-199704000-00012
10.1038/cdd.2017.105
10.3390/cells10113149
10.1038/362059a0
10.1038/ncomms5202
10.3390/cancers14184499
10.1101/cshperspect.a000919
10.1016/S0140-6736(08)61589-5
10.1074/jbc.M112.340638
10.1073/pnas.0805326105
10.1016/j.biocel.2010.10.017
10.1126/science.1222951
10.1016/0166-2236(93)90078-Z
10.1038/s41593-018-0235-9
10.4161/cc.10.10.15642
10.1073/pnas.0915166107
10.1080/13506129.2016.1257986
10.18632/oncotarget.25631
10.2174/1389557520999201124212347
10.1002/j.1460-2075.1992.tb05434.x
10.1002/path.1711570304
10.1016/S0072-9752(07)01223-7
10.3389/fonc.2015.00284
10.1093/nar/gkt305
10.1101/cshperspect.a023614
10.1074/jbc.M116.762096
10.1038/srep32535
10.3389/fmolb.2022.895887
10.1038/ncb2641
10.1016/j.ccr.2012.03.042
10.1158/1538-7445.AM2020-3432
10.1039/C1CS15112F
10.1016/j.bbrc.2017.05.111
10.1200/JCO.2017.35.15_suppl.e14099
10.3389/fonc.2020.595187
10.1073/pnas.1211557109
10.1111/j.1440-1789.1996.tb00155.x
10.1126/science.1261669
10.3390/jpm11080808
10.1038/s41388-018-0652-y
10.3390/cancers10060154
10.7554/eLife.61487
10.1007/s00415-014-7373-0
10.1038/368756a0
10.3390/cancers10060166
10.1038/s41467-018-06953-0
10.1073/pnas.89.15.7262
10.1016/j.chembiol.2018.06.013
10.3390/biom10040548
10.1007/s10549-010-0851-x
10.1016/j.cbpa.2022.102230
10.3390/cancers13020269
10.1038/s41419-018-0463-7
10.1083/jcb.201110131
10.1038/nrm2395
10.1016/0042-6822(88)90486-2
10.18632/oncotarget.9133
10.1016/j.molcel.2021.05.004
10.1038/onc.2017.152
10.1016/j.cell.2017.08.028
10.1002/humu.23035
10.3389/fphar.2023.1215995
10.1038/352077a0
10.1038/s41572-020-0210-0
10.1042/BSR20130065
10.1016/j.biomaterials.2013.10.062
10.1038/nature02391
10.1002/jat.2854
10.1007/s12282-014-0537-z
10.1038/s41419-020-2658-y
10.1038/s41467-018-05763-8
10.1007/s10549-018-4753-7
10.1016/j.ejca.2015.12.002
10.1111/j.1365-2133.2010.09657.x
10.1111/neup.12355
10.18632/oncotarget.2432
10.3390/cancers10090288
10.1016/j.canlet.2017.09.053
10.2174/1389203720666190610092840
10.4161/pri.27776
10.1074/jbc.M302458200
10.1038/s41418-022-00980-7
10.1016/j.tig.2004.01.008
10.3390/cancers9120172
10.1038/s41568-020-00312-2
10.1021/acschembio.9b00748
10.1186/s13045-021-01169-0
10.1038/s41580-019-0110-x
10.1007/s40291-022-00583-5
10.1002/ijc.30425
10.1186/1756-9966-32-72
10.1016/j.tibs.2007.11.003
10.1074/jbc.M115.690172
10.1073/pnas.1211550109
10.5315/wjh.v6.i3.55
10.1038/s41591-018-0049-z
10.1126/science.277.5323.228
10.1038/s41586-022-04670-9
10.3390/ijms23094883
10.3390/cancers14174187
10.1016/j.tibs.2014.04.001
10.1073/pnas.1303002110
10.1016/j.molcel.2019.10.028
10.1038/s41467-019-13305-z
10.3390/biom10020303
10.1038/nature17946
10.1146/annurev-biochem-061516-045115
10.3892/ol.2017.5901
10.1038/s41598-021-98547-y
10.1039/c3dt50513h
10.1073/pnas.92.10.4407
10.1016/j.ctrv.2018.09.004
10.1007/s11033-019-05093-y
10.1158/1535-7163.MCT-15-0237
10.1038/nrm3810
10.1016/j.molcel.2018.06.012
10.1016/S1383-5742(00)00011-9
10.1038/nature02392
10.1016/j.ejca.2017.06.023
10.1002/j.1460-2075.1994.tb06656.x
10.1101/gad.190678.112
10.1186/s13058-020-01296-5
10.1074/jbc.RA118.004671
10.1101/cshperspect.a033928
10.1158/0008-5472.CAN-16-3247
10.1016/j.molcel.2019.10.027
10.1038/cdd.2016.48
10.1038/nchembio.546
10.1021/bi500825d
10.1016/j.jmb.2009.11.013
10.1016/S0889-8529(05)70039-6
10.4161/cc.22778
10.3389/fonc.2015.00289
10.1021/ar900179t
10.1021/acs.accounts.7b00473
10.1186/s13058-021-01406-x
10.1021/acs.biochem.9b00796
10.1074/jbc.M109.075861
10.1016/S0968-0004(00)88954-9
10.1038/ng0892-321
10.1158/0008-5472.CAN-08-0349
10.1007/s11010-013-1688-5
10.3390/cancers10060188
10.1073/pnas.1610421113
10.1038/ncb3427
10.1038/s41573-022-00571-8
10.4161/cc.21020
10.1146/annurev-biochem-061516-045104
10.3390/ijms231911023
10.1093/jmcb/mjz005
10.5812/semj.94641
10.1016/j.cell.2012.02.022
10.1089/hum.2016.139
10.1080/13506129.2018.1549825
10.1016/j.tcb.2020.02.001
10.1089/hum.2017.218
10.1093/bmb/ldn013
10.18632/oncotarget.11774
10.1038/nrc.2017.109
10.1093/annonc/mdt303
10.1177/1947601910383277
ContentType Journal Article
Copyright 2024 The Authors
2024 The Authors.
2024 The Authors 2024
Copyright_xml – notice: 2024 The Authors
– notice: 2024 The Authors.
– notice: 2024 The Authors 2024
DBID 6I.
AAFTH
AAYXX
CITATION
NPM
7S9
L.6
7X8
5PM
DOA
DOI 10.1016/j.heliyon.2024.e26260
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
PubMed
AGRICOLA
AGRICOLA - Academic
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
AGRICOLA
AGRICOLA - Academic
MEDLINE - Academic
DatabaseTitleList
AGRICOLA

MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 2405-8440
ExternalDocumentID oai_doaj_org_article_d2b3aada06e44327b29bff0937937283
PMC10881377
38390040
10_1016_j_heliyon_2024_e26260
S2405844024022916
Genre Journal Article
Review
GroupedDBID 0R~
457
53G
5VS
6I.
AAEDW
AAFTH
AAFWJ
AALRI
AAYWO
ABMAC
ACGFS
ACLIJ
ACVFH
ADBBV
ADCNI
ADEZE
ADVLN
AEUPX
AEXQZ
AFJKZ
AFPKN
AFPUW
AFTJW
AGHFR
AIGII
AITUG
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AOIJS
APXCP
BAWUL
BCNDV
DIK
EBS
FDB
GROUPED_DOAJ
HYE
KQ8
M~E
O9-
OK1
ROL
RPM
SSZ
AAYXX
CITATION
EJD
IPNFZ
RIG
NPM
7S9
L.6
7X8
5PM
ID FETCH-LOGICAL-c567t-4907f4ac510f9540642b1710cf19fb228df9b4c74545d27f00d2ba1e71325b273
IEDL.DBID DOA
ISICitedReferencesCount 2
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001187987600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2405-8440
IngestDate Fri Oct 03 12:41:58 EDT 2025
Tue Sep 30 17:10:40 EDT 2025
Wed Jul 02 05:10:41 EDT 2025
Fri Aug 22 20:38:40 EDT 2025
Mon Jul 21 05:51:14 EDT 2025
Thu Oct 09 00:44:42 EDT 2025
Tue Nov 18 22:25:28 EST 2025
Sat Nov 08 17:57:18 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Mutant p53
Cancer treatment
Prion-like aggregation
Triple-negative breast cancer
Language English
License This is an open access article under the CC BY license.
2024 The Authors.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c567t-4907f4ac510f9540642b1710cf19fb228df9b4c74545d27f00d2ba1e71325b273
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Review-3
ORCID 0000-0002-2311-6554
OpenAccessLink https://doaj.org/article/d2b3aada06e44327b29bff0937937283
PMID 38390040
PQID 3153847078
PQPubID 24069
ParticipantIDs doaj_primary_oai_doaj_org_article_d2b3aada06e44327b29bff0937937283
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10881377
proquest_miscellaneous_3182879281
proquest_miscellaneous_3153847078
pubmed_primary_38390040
crossref_primary_10_1016_j_heliyon_2024_e26260
crossref_citationtrail_10_1016_j_heliyon_2024_e26260
elsevier_sciencedirect_doi_10_1016_j_heliyon_2024_e26260
PublicationCentury 2000
PublicationDate 2024-02-29
PublicationDateYYYYMMDD 2024-02-29
PublicationDate_xml – month: 02
  year: 2024
  text: 2024-02-29
  day: 29
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Heliyon
PublicationTitleAlternate Heliyon
PublicationYear 2024
Publisher Elsevier Ltd
Elsevier
Publisher_xml – name: Elsevier Ltd
– name: Elsevier
References Davie (bib185) 2008; 86
Bykov, Zache, Stridh, Westman, Bergman, Selivanova, Wiman (bib130) 2005; 24
Bardhan, Bruckner-Tuderman, Chapple, Fine, Harper, Has, Magin, Marinkovich, Marshall, McGrath, Mellerio, Polson, Heagerty (bib193) 2020; 6
Goldschmidt, Teng, Riek, Eisenberg (bib152) 2010; 107
Boeckler, Joerger, Jaggi, Rutherford, Veprintsev, Fersht (bib140) 2008; 105
Wang, Kaufman (bib25) 2012; 197
Itakura, Chakravarty, Jakobson, Jarosz (bib72) 2020; 77
Ory, Legros, Auguin, Soussi (bib77) 1994; 13
Biel, Aryal, Gerber, Trevino, Mizuno, Rao (bib160) 2020; 11
Pucci, Crispini, Sanz Mendiguchia, Pirillo, Ghedini, Morelli, De Bartolo (bib106) 2013; 42
Padayachee, Singh (bib173) 2020; 7
Kastenhuber, Lowe (bib10) 2017; 170
Rangel, Costa, Vieira, Silva (bib99) 2014; 8
Gautam, Karmakar, Batra, Sharma, Pradhan, Singh, Kundu, Chowdhury (bib146) 2017; 1865
Duffy, Synnott, Crown (bib101) 2017; 83
Duffy, Tang, Rajaram, O'Grady, Crown (bib125) 2022; 14
Arin, Grimberg, Schumann, De Almeida, Chang, Tadini, Kohlhase, Krieg, Bruckner‐Tuderman, Has (bib192) 2010; 162
Soto, Pritzkow (bib56) 2018; 21
Chiti, Dobson (bib60) 2017; 86
Lieberman, Wustman, Huertas, Powe, Pine, Khanna, Schlossmacher, Ringe, Petsko (bib201) 2007; 3
Billant, Léon, Le Guellec, Friocourt, Blondel, Voisset (bib68) 2016; 7
Butturini, Butera, Pacchiana, Carcereri de Prati, Mariotto, Donadelli (bib118) 2021; 10
Hayes, Seminara, Crowley (bib198) 1998; 27
Schulz-Heddergott, Moll (bib40) 2018; 10
Riley, Sontag, Chen, Levine (bib33) 2008; 9
Tamura, Hunger, Fernandes, Laurindo, Costanzi-Strauss, Strauss (bib167) 2017; 28
Wang, Liu, Zhang, Zhang (bib113) 2023; 14
Pairawan, Zhao, Yuca, Annis, Evans, Sutton, Carvajal, Ren, Santiago, Guerlavais, Akcakanat, Tapia, Yang, Bose, Zheng, Dumbrava, Aivado, Meric-Bernstam (bib156) 2021; 23
Friedler, Veprintsev, Hansson, Fersht (bib120) 2003; 278
Li, Li (bib184) 2004; 20
de Oliveira, Petronilho, Pedrote, Marques, Vieira, Cino, Silva (bib52) 2020; 10
Ghosh, Salot, Sengupta, Navalkar, Ghosh, Jacob, Das, Kumar, Jha, Sahay, Mehra, Mohite, Ghosh, Kombrabail, Krishnamoorthy, Chaudhari, Maji (bib14) 2017; 24
Rodriguez, Choudhury, Kolukula, Vietsch, Catania, Preet, Reynoso, Bargonetti, Wellstein, Albanese, Avantaggiati (bib157) 2012; 11
Tang, Su, Gu, Rustgi (bib39) 2020; 6
da Costa, Campos, Santos, Guedes-da-Silva, Martins-Dinis, Zanphorlin, Ramos, Rangel, Silva (bib148) 2018; 9
Park, Park, Pentek, Liebman (bib76) 2021; 24
Synnott, Bauer, Madden, Murray, Klinger, O'Donovan, O'Connor, Gallagher, Crown, Fersht (bib133) 2018; 414
Li, Bentley, Anderson, Wiblin, Cleary, Koustoulidou, Hassanali, Yates, Greig, Nordkamp (bib162) 2017; 77
Goldhirsch, Winer, Coates, Gelber, Piccart-Gebhart, Thurlimann, Senn, Panel (bib4) 2013; 24
Goedert (bib182) 1993; 16
Bom, Freitas, Moreira, Ferraz, Sanches, Gomes, Valente, Cordeiro, Silva (bib58) 2010; 285
Rosen, Siddique, Patterson, Figlewicz, Sapp, Hentati, Donaldson, Goto, O'Regan, Deng (bib195) 1993; 362
Perdrix, Najem, Saussez, Awada, Journe, Ghanem, Krayem (bib127) 2017; 9
Silva, Lima, Foguel, Cordeiro (bib86) 2008; 33
Xu, Reumers, Couceiro, De Smet, Gallardo, Rudyak, Cornelis, Rozenski, Zwolinska, Marine, Lambrechts, Suh, Rousseau, Schymkowitz (bib92) 2011; 7
Needham, Guerriero, Brodsky (bib23) 2019; 11
Binayke, Mishra, Suman, Das, Chander (bib31) 2019; 83
Kogan, Carpizo (bib35) 2018; 10
Kartner, Augustinas, Jensen, Naismith, Riordan (bib190) 1992; 1
Freed-Pastor, Prives (bib43) 2012; 26
Liang, Besch-Williford, Benakanakere, Thorpe, Hyder (bib129) 2011; 125
Idres, McMillan, Idris (bib180) 2022; 26
Silva, De Moura Gallo, Costa, Rangel (bib13) 2014; 39
Bykov, Eriksson, Bianchi, Wiman (bib102) 2018; 18
Chino, Mizushima (bib22) 2020; 30
Yin, Duan, Bian, Yu (bib5) 2020; 22
Alalem, Bhosale, Ranjan, Yamamoto, Kaida, Nishikawa, Parrales, Farooki, Anant, Padhye, Iwakuma (bib114) 2022; 14
DeToma, Salamekh, Ramamoorthy, Lim (bib53) 2012; 41
Borrero, El-Deiry (bib27) 2021; 1876
Billant, Friocourt, Roux, Voisset (bib67) 2021; 13
Ferretti, Quarti, Dos Santos, Rangel, Silva (bib98) 2022; 23
Wilcken, Wang, Boeckler, Fersht (bib89) 2012; 109
Plante-Bordeneuve (bib194) 2014; 261
Zhang, Bergman, Wiman, Bykov (bib117) 2018; 25
Oztas, Yalcinkaya (bib186) 2017; 6
Navalkar, Ghosh, Pandey, Paul, Datta, Maji (bib17) 2020; 59
Yadav, Yadav, Vashistha, Pandey, Dwivedi (bib57) 2019; 20
Hafner, Bulyk, Jambhekar, Lahav (bib30) 2019; 20
Shi, Norberg, Vakifahmetoglu-Norberg (bib159) 2021; 10
D'Orazi, Givol (bib7) 2012; 11
Ubby, Krueger, Rosato, Qian, Chang, Sabapathy (bib171) 2019; 38
Boulyjenkov (bib199) 1997; 75
Liu, Liu, Li, Yao (bib187) 2022; 23
Chakravarty, Smejkal, Itakura, Garcia, Jarosz (bib71) 2020; 77
Walerych, Lisek, Del Sal (bib137) 2015; 5
Bauer, Kramer, Settanni, Jones, Ni, Khan Tareque, Fersht, Spencer, Joerger (bib139) 2020; 15
Reis (bib166) 2019
Parrales, Ranjan, Iyer, Padhye, Weir, Roy, Iwakuma (bib112) 2016; 18
Fronza, Inga, Monti, Scott, Campomenosi, Menichini, Ottaggio, Viaggi, Burns, Gold, Abbondandolo (bib70) 2000; 462
Misra, Naz, Kondaiah, Bhattacharya (bib168) 2014; 35
Komor, Kim, Packer, Zuris, Liu (bib175) 2016; 533
Blanden, Yu, Aaron, Gilleran, Augeri, O'Dell, Olson, Kimball, Emge, Movileanu (bib108) 2015; 88
Liu, Wilcken, Joerger, Chuckowree, Amin, Spencer, Fersht (bib138) 2013; 41
Ss, Jubie, Naresh, Wadhwani, Sk (bib94) 2020
Zarate, Hopkin (bib189) 2008; 372
Blanden, Yu, Blayney, Demas, Ha, Liu, Withers, Carpizo, Loh (bib104) 2020; 9
Iwasaki (bib183) 2017; 37
Joerger, Fersht (bib121) 2010; 2
Milner (bib65) 1995; 20
Naresh, Wadhwani, Jubie (bib93) 2021; 21
Krayem, Journe, Wiedig, Morandini, Najem, Salès, van Kempen, Sibille, Awada, Marine (bib128) 2016; 55
Carstea, Morris, Coleman, Loftus, Zhang, Cummings, Gu, Rosenfeld, Pavan, Krizman, Nagle, Polymeropoulos, Sturley, Ioannou, Higgins, Comly, Cooney, Brown, Kaneski, Blanchette-Mackie, Dwyer, Neufeld, Chang, Liscum, Strauss, Ohno, Zeigler, Carmi, Sokol, Markie, O'Neill, van Diggelen, Elleder, Patterson, Brady, Vanier, Pentchev, Tagle (bib200) 1997; 277
Logue, McGrath, Cleary, Greene, Mnich, Almanza, Chevet, Dwyer, Oommen, Legembre, Godey, Madden, Leuzzi, Obacz, Zeng, Patterson, Jager, Gorman, Samali (bib150) 2018; 9
Monti, Bosco, Gomes, Saraiva, Fronza, Inga (bib69) 2019; 150
Yu, Vazquez, Levine, Carpizo (bib109) 2012; 21
Yu, Na, Zaman, Withers, Gilleran, Blayney, Bencivenga, Blanden, Liu, Boothman (bib111) 2020; 80
Silva, Rangel, Costa, Cordeiro, De Moura Gallo (bib88) 2013; 33
Alalem (bib8) 2020
Chen, Cubillos-Ruiz (bib21) 2021; 21
Bom, Rangel, Costa, de Oliveira, Sanches, Braga, Gava, Ramos, Cepeda, Stumbo (bib51) 2012; 287
Zhang, Bykov, Wiman, Zawacka-Pankau (bib123) 2018; 9
Yoon, Byun, Kwon, Hwang, Chu, Hiraki, Jo, Weins, Hakroush, Cebulla, Sykes, Greka, Mundel, Fisher, Mandinova, Lee (bib32) 2015; 349
Takeda, Takahashi (bib197) 1996; 16
Bauer, Joerger, Fersht (bib132) 2016; 113
Moll, Valea, Chumas (bib74) 1997; 16
Duffy, Synnott, Crown (bib20) 2018; 170
Hoyos, Greenbaum, Levine (bib28) 2022; 29
Porter, Gown, Kramp, Coltrera (bib83) 1992; 140
Florio, Folli, Cianci, Del Rio, Zanotti, Berni (bib147) 2015; 290
Reza, Ferdous, Emon, Islam, Mohiuddin, Hossain (bib136) 2021; 11
Lee, Jeong, Jeon, Kim, Kang (bib95) 2010; 24
Selkoe (bib181) 2008; 89
Sabapathy, Lane (bib100) 2018; 15
Chang, Graves, Guerlavais, Tovar, Packman, To, Olson, Kesavan, Gangurde, Mukherjee, Baker, Darlak, Elkin, Filipovic, Qureshi, Cai, Berry, Feyfant, Shi, Horstick, Annis, Manning, Fotouhi, Nash, Vassilev, Sawyer (bib155) 2013; 110
Hainaut, Milner (bib79) 1992; 11
Jiang, Lucas, Avery-Kiejda, Wade, debock, Thorne, Allen, Hersey, Zhang (bib141) 2008; 68
Ha, Prela, Carpizo, Loh (bib34) 2022; 9
Synnott, Murray, McGowan, Kiely, Kiely, O'Donovan, O'Connor, Gallagher, Crown, Duffy (bib19) 2017; 140
Zhang, Li, Li, Liu, Li, Li, Xu, Zhang, Chandler, Lin, Hu, Xu, Lam (bib178) 2018; 29
Hassin, Oren (bib163) 2023; 22
Loh (bib103) 2020; 10
Chen, Chen, Keshamouni, Kanapathipillai (bib154) 2017; 489
Silva, Cino, Soares, Ferreira, A.P.d.O (bib15) 2018; 51
Formigari, Gregianin, Irato (bib46) 2013; 33
Babikir, Afjei, Paulmurugan, Massoud (bib6) 2018; 71
Bartek, Iggo, Gannon, Lane (bib81) 1990; 5
Rangel, Ferretti, Costa, Andrade, Carvalho, Costa, Silva (bib122) 2019; 294
Vieler, Sanyal (bib49) 2018; 10
Haapaniemi, Botla, Persson, Schmierer, Taipale (bib176) 2018; 24
Burguin, Diorio, Durocher (bib1) 2021; 11
Kavousipour, Mokarram, Barazesh, Arabizadeh, Razban, Mostafavipour, Mohammadi, Abolmaali (bib3) 2020; 21
Tanaka, Chien, Naber, Cooke, Weissman (bib63) 2004; 428
Hientz, Mohr, Bhakta-Guha, Efferth (bib144) 2017; 8
Jiang, Cao, Sawaya, Abskharon, Ge, DeTure, Dickson, Fu, Ogorzalek Loo, Loo, Eisenberg (bib55) 2022; 605
Scott, Frydman (bib202) 2003; 232
Knowles, Vendruscolo, Dobson (bib61) 2014; 15
Zhang, Hu, Wang, Yao, Wang, Liang, Li, Shi, Chen, Fang (bib153) 2017; 36
Ilbeigi, Naeimzadeh, Davoodabadi Farahani, Rafi Monjezi, Dastsooz, Daraei, Farahani, Dastgheib, Mansoori, Tabei (bib2) 2021; 34
Costa, de Oliveira, Cino, Soares, Rangel, Silva (bib11) 2016; 8
Yu, Blanden, Narayanan, Jayakumar, Lubin, Augeri, Kimball, Loh, Carpizo (bib45) 2014; 5
King, Diaz-Avalos (bib62) 2004; 428
Low, Goh, Koh, Lim, Wang (bib164) 2019; 10
Eriksson, Ceder, Bykov, Wiman (bib37) 2019; 11
Puca, Nardinocchi, Porru, Simon, Rechavi, Leonetti, Givol, D'Orazi (bib105) 2011; 10
Xiao, Zhou, Fu, Liang, Deng, Liu, Liu (bib179) 2017; 13
Eisenberg, Sawaya (bib59) 2017; 86
Garufi, Trisciuoglio, Porru, Leonetti, Stoppacciaro, D'Orazi, Avantaggiati, Crispini, Pucci, D'Orazi (bib107) 2013; 32
Prusiner (bib64) 2012; 336
Moll, LaQuaglia, Benard, Riou (bib75) 1995; 92
Moll, Riou, Levine (bib82) 1992; 89
Sipe, Benson, Buxbaum, Ikeda, Merlini, Saraiva, Westermark (bib85) 2016; 23
Cino, Soares, Pedrote, de Oliveira, Silva (bib115) 2016; 6
La Spada, Wilson, Lubahn, Harding, Fischbeck (bib191) 1991; 352
Gamble, Milner (bib78) 1988; 162
Zhu, Pan, Bei, Li, Liang, Xu, Fu (bib42) 2020; 10
Bouaoun, Sonkin, Ardin, Hollstein, Byrnes, Zavadil, Olivier (bib50) 2016; 37
Braicu, Pileczki, Irimie, Berindan-Neagoe (bib172) 2013; 381
Rejeeth, Kannan (bib169) 2016; 23
Milner, Medcalf (bib66) 1991; 65
Elledge, Clark, Fuqua, Y
Perri (10.1016/j.heliyon.2024.e26260_bib38) 2016; 4
Scott (10.1016/j.heliyon.2024.e26260_bib202) 2003; 232
Riley (10.1016/j.heliyon.2024.e26260_bib33) 2008; 9
Knowles (10.1016/j.heliyon.2024.e26260_bib61) 2014; 15
Chino (10.1016/j.heliyon.2024.e26260_bib22) 2020; 30
Misra (10.1016/j.heliyon.2024.e26260_bib168) 2014; 35
Eisenberg (10.1016/j.heliyon.2024.e26260_bib59) 2017; 86
Parrales (10.1016/j.heliyon.2024.e26260_bib112) 2016; 18
Wang (10.1016/j.heliyon.2024.e26260_bib113) 2023; 14
D'Orazi (10.1016/j.heliyon.2024.e26260_bib7) 2012; 11
Yao (10.1016/j.heliyon.2024.e26260_bib158) 2010; 1
Wang (10.1016/j.heliyon.2024.e26260_bib96) 2017; 114
Rodriguez (10.1016/j.heliyon.2024.e26260_bib157) 2012; 11
Perdrix (10.1016/j.heliyon.2024.e26260_bib127) 2017; 9
Soragni (10.1016/j.heliyon.2024.e26260_bib151) 2016; 29
Needham (10.1016/j.heliyon.2024.e26260_bib23) 2019; 11
Yu (10.1016/j.heliyon.2024.e26260_bib109) 2012; 21
Navalkar (10.1016/j.heliyon.2024.e26260_bib17) 2020; 59
Formigari (10.1016/j.heliyon.2024.e26260_bib46) 2013; 33
Xiao (10.1016/j.heliyon.2024.e26260_bib179) 2017; 13
Low (10.1016/j.heliyon.2024.e26260_bib164) 2019; 10
Garufi (10.1016/j.heliyon.2024.e26260_bib107) 2013; 32
Kartner (10.1016/j.heliyon.2024.e26260_bib190) 1992; 1
Silva (10.1016/j.heliyon.2024.e26260_bib86) 2008; 33
Cino (10.1016/j.heliyon.2024.e26260_bib115) 2016; 6
Rangel (10.1016/j.heliyon.2024.e26260_bib122) 2019; 294
Rangel (10.1016/j.heliyon.2024.e26260_bib99) 2014; 8
Sipe (10.1016/j.heliyon.2024.e26260_bib85) 2016; 23
Krayem (10.1016/j.heliyon.2024.e26260_bib128) 2016; 55
Ilbeigi (10.1016/j.heliyon.2024.e26260_bib2) 2021; 34
Martinez (10.1016/j.heliyon.2024.e26260_bib170) 2002; 99
Levy (10.1016/j.heliyon.2024.e26260_bib18) 2011; 43
Duffy (10.1016/j.heliyon.2024.e26260_bib20) 2018; 170
Billant (10.1016/j.heliyon.2024.e26260_bib68) 2016; 7
Ghosh (10.1016/j.heliyon.2024.e26260_bib14) 2017; 24
Fronza (10.1016/j.heliyon.2024.e26260_bib70) 2000; 462
Chang (10.1016/j.heliyon.2024.e26260_bib155) 2013; 110
Bouaoun (10.1016/j.heliyon.2024.e26260_bib50) 2016; 37
Komor (10.1016/j.heliyon.2024.e26260_bib175) 2016; 533
Plante-Bordeneuve (10.1016/j.heliyon.2024.e26260_bib194) 2014; 261
Piyawajanusorn (10.1016/j.heliyon.2024.e26260_bib126) 2019; 16
Naresh (10.1016/j.heliyon.2024.e26260_bib93) 2021; 21
Liang (10.1016/j.heliyon.2024.e26260_bib129) 2011; 125
Takeda (10.1016/j.heliyon.2024.e26260_bib197) 1996; 16
Batir (10.1016/j.heliyon.2024.e26260_bib174) 2019; 46
Butturini (10.1016/j.heliyon.2024.e26260_bib118) 2021; 10
Tang (10.1016/j.heliyon.2024.e26260_bib39) 2020; 6
Reis (10.1016/j.heliyon.2024.e26260_bib166) 2019
Lemberg (10.1016/j.heliyon.2024.e26260_bib26) 2021; 81
Medori (10.1016/j.heliyon.2024.e26260_bib203) 1992; 326
Walerych (10.1016/j.heliyon.2024.e26260_bib137) 2015; 5
Shang (10.1016/j.heliyon.2024.e26260_bib145) 2002; 295
Kanapathipillai (10.1016/j.heliyon.2024.e26260_bib97) 2018; 10
Binayke (10.1016/j.heliyon.2024.e26260_bib31) 2019; 83
Hainaut (10.1016/j.heliyon.2024.e26260_bib79) 1992; 11
Sabapathy (10.1016/j.heliyon.2024.e26260_bib100) 2018; 15
Elledge (10.1016/j.heliyon.2024.e26260_bib73) 1994; 54
Goedert (10.1016/j.heliyon.2024.e26260_bib182) 1993; 16
Jiang (10.1016/j.heliyon.2024.e26260_bib55) 2022; 605
Benson (10.1016/j.heliyon.2024.e26260_bib84) 2018; 25
Sailer (10.1016/j.heliyon.2024.e26260_bib177) 2018; 9
Li (10.1016/j.heliyon.2024.e26260_bib162) 2017; 77
Bom (10.1016/j.heliyon.2024.e26260_bib58) 2010; 285
Zhang (10.1016/j.heliyon.2024.e26260_bib178) 2018; 29
van den Berg (10.1016/j.heliyon.2024.e26260_bib80) 1989; 157
Porter (10.1016/j.heliyon.2024.e26260_bib83) 1992; 140
Bykov (10.1016/j.heliyon.2024.e26260_bib102) 2018; 18
Kavousipour (10.1016/j.heliyon.2024.e26260_bib3) 2020; 21
Zhang (10.1016/j.heliyon.2024.e26260_bib117) 2018; 25
Yu (10.1016/j.heliyon.2024.e26260_bib111) 2020; 80
Chakravarty (10.1016/j.heliyon.2024.e26260_bib71) 2020; 77
Logue (10.1016/j.heliyon.2024.e26260_bib150) 2018; 9
Lorenzo (10.1016/j.heliyon.2024.e26260_bib188) 1994; 368
Rosen (10.1016/j.heliyon.2024.e26260_bib195) 1993; 362
de Oliveira (10.1016/j.heliyon.2024.e26260_bib52) 2020; 10
Schulz-Heddergott (10.1016/j.heliyon.2024.e26260_bib40) 2018; 10
Muller (10.1016/j.heliyon.2024.e26260_bib91) 2013; 15
Pairawan (10.1016/j.heliyon.2024.e26260_bib156) 2021; 23
Iwasaki (10.1016/j.heliyon.2024.e26260_bib183) 2017; 37
Li (10.1016/j.heliyon.2024.e26260_bib184) 2004; 20
Hassin (10.1016/j.heliyon.2024.e26260_bib163) 2023; 22
DeToma (10.1016/j.heliyon.2024.e26260_bib53) 2012; 41
Shi (10.1016/j.heliyon.2024.e26260_bib159) 2021; 10
Friedler (10.1016/j.heliyon.2024.e26260_bib120) 2003; 278
Moll (10.1016/j.heliyon.2024.e26260_bib75) 1995; 92
Haapaniemi (10.1016/j.heliyon.2024.e26260_bib176) 2018; 24
Hetz (10.1016/j.heliyon.2024.e26260_bib24) 2015; 17
Costa (10.1016/j.heliyon.2024.e26260_bib11) 2016; 8
Alalem (10.1016/j.heliyon.2024.e26260_bib114) 2022; 14
Boeckler (10.1016/j.heliyon.2024.e26260_bib140) 2008; 105
Synnott (10.1016/j.heliyon.2024.e26260_bib19) 2017; 140
Idres (10.1016/j.heliyon.2024.e26260_bib180) 2022; 26
Hu (10.1016/j.heliyon.2024.e26260_bib9) 2021; 14
Parrales (10.1016/j.heliyon.2024.e26260_bib124) 2015; 5
Salim (10.1016/j.heliyon.2024.e26260_bib135) 2016; 7
Yin (10.1016/j.heliyon.2024.e26260_bib5) 2020; 22
Itakura (10.1016/j.heliyon.2024.e26260_bib72) 2020; 77
Davie (10.1016/j.heliyon.2024.e26260_bib185) 2008; 86
Hayes (10.1016/j.heliyon.2024.e26260_bib198) 1998; 27
Zhang (10.1016/j.heliyon.2024.e26260_bib153) 2017; 36
Alalem (10.1016/j.heliyon.2024.e26260_bib8) 2020
Vijayakumaran (10.1016/j.heliyon.2024.e26260_bib119) 2015; 5
Bardhan (10.1016/j.heliyon.2024.e26260_bib193) 2020; 6
Goldhirsch (10.1016/j.heliyon.2024.e26260_bib4) 2013; 24
Braicu (10.1016/j.heliyon.2024.e26260_bib172) 2013; 381
Boulyjenkov (10.1016/j.heliyon.2024.e26260_bib199) 1997; 75
Yoon (10.1016/j.heliyon.2024.e26260_bib32) 2015; 349
Lee (10.1016/j.heliyon.2024.e26260_bib95) 2010; 24
King (10.1016/j.heliyon.2024.e26260_bib62) 2004; 428
Billant (10.1016/j.heliyon.2024.e26260_bib67) 2021; 13
Tanaka (10.1016/j.heliyon.2024.e26260_bib63) 2004; 428
Hientz (10.1016/j.heliyon.2024.e26260_bib144) 2017; 8
Wang (10.1016/j.heliyon.2024.e26260_bib47) 2012; 109
Ferretti (10.1016/j.heliyon.2024.e26260_bib98) 2022; 23
Reza (10.1016/j.heliyon.2024.e26260_bib136) 2021; 11
Arin (10.1016/j.heliyon.2024.e26260_bib192) 2010; 162
Chiti (10.1016/j.heliyon.2024.e26260_bib60) 2017; 86
Bauer (10.1016/j.heliyon.2024.e26260_bib132) 2016; 113
Loh (10.1016/j.heliyon.2024.e26260_bib103) 2020; 10
Bauer (10.1016/j.heliyon.2024.e26260_bib139) 2020; 15
Pechackova (10.1016/j.heliyon.2024.e26260_bib142) 2016; 7
Wilcken (10.1016/j.heliyon.2024.e26260_bib89) 2012; 109
Kwan (10.1016/j.heliyon.2024.e26260_bib36) 2023; 72
Zhu (10.1016/j.heliyon.2024.e26260_bib42) 2020; 10
La Spada (10.1016/j.heliyon.2024.e26260_bib191) 1991; 352
Duffy (10.1016/j.heliyon.2024.e26260_bib44) 2022; vol. 79
Soto (10.1016/j.heliyon.2024.e26260_bib56) 2018; 21
Ha (10.1016/j.heliyon.2024.e26260_bib34) 2022; 9
Vieler (10.1016/j.heliyon.2024.e26260_bib49) 2018; 10
Puca (10.1016/j.heliyon.2024.e26260_bib105) 2011; 10
Lieberman (10.1016/j.heliyon.2024.e26260_bib201) 2007; 3
Park (10.1016/j.heliyon.2024.e26260_bib76) 2021; 24
Jiang (10.1016/j.heliyon.2024.e26260_bib141) 2008; 68
Freed-Pastor (10.1016/j.heliyon.2024.e26260_bib43) 2012; 26
Padayachee (10.1016/j.heliyon.2024.e26260_bib173) 2020; 7
Xu (10.1016/j.heliyon.2024.e26260_bib92) 2011; 7
Moll (10.1016/j.heliyon.2024.e26260_bib74) 1997; 16
Florio (10.1016/j.heliyon.2024.e26260_bib147) 2015; 290
Chen (10.1016/j.heliyon.2024.e26260_bib154) 2017; 489
Hafner (10.1016/j.heliyon.2024.e26260_bib30) 2019; 20
Burguin (10.1016/j.heliyon.2024.e26260_bib1) 2021; 11
Synnott (10.1016/j.heliyon.2024.e26260_bib131) 2017
Carstea (10.1016/j.heliyon.2024.e26260_bib200) 1997; 277
Moll (10.1016/j.heliyon.2024.e26260_bib82) 1992; 89
Ss (10.1016/j.heliyon.2024.e26260_bib110) 2021; 21
Goldschmidt (10.1016/j.heliyon.2024.e26260_bib152) 2010; 107
Zarate (10.1016/j.heliyon.2024.e26260_bib189) 2008; 372
Tonsing-Carter (10.1016/j.heliyon.2024.e26260_bib143) 2015; 14
Ss (10.1016/j.heliyon.2024.e26260_bib94) 2020
Ubby (10.1016/j.heliyon.2024.e26260_bib171) 2019; 38
Zhang (10.1016/j.heliyon.2024.e26260_bib123) 2018; 9
Tamura (10.1016/j.heliyon.2024.e26260_bib167) 2017; 28
Gamble (10.1016/j.heliyon.2024.e26260_bib78) 1988; 162
Blanden (10.1016/j.heliyon.2024.e26260_bib108) 2015; 88
Pucci (10.1016/j.heliyon.2024.e26260_bib106) 2013; 42
de Oliveira (10.1016/j.heliyon.2024.e26260_bib12) 2015; 5
Synnott (10.1016/j.heliyon.2024.e26260_bib133) 2018; 414
Sanches (10.1016/j.heliyon.2024.e26260_bib149) 2014; 5
Bykov (10.1016/j.heliyon.2024.e26260_bib130) 2005; 24
Gautam (10.1016/j.heliyon.2024.e26260_bib146) 2017; 1865
Oztas (10.1016/j.heliyon.2024.e26260_bib186) 2017; 6
da Costa (10.1016/j.heliyon.2024.e26260_bib148) 2018; 9
Kastenhuber (10.1016/j.heliyon.2024.e26260_bib10) 2017; 170
Duffy (10.1016/j.heliyon.2024.e26260_bib101) 2017; 83
Yu (10.1016/j.heliyon.2024.e26260_bib45) 2014; 5
Joerger (10.1016/j.heliyon.2024.e26260_bib121) 2010; 2
Selkoe (10.1016/j.heliyon.2024.e26260_bib181) 2008; 89
Yadav (10.1016/j.heliyon.2024.e26260_bib57) 2019; 20
Rejeeth (10.1016/j.heliyon.2024.e26260_bib169) 2016; 23
Kamada (10.1016/j.heliyon.2024.e26260_bib29) 2016; 106
Monti (10.1016/j.heliyon.2024.e26260_bib69) 2019; 150
Wang (10.1016/j.heliyon.2024.e26260_bib25) 2012; 197
Kogan (10.1016/j.heliyon.2024.e26260_bib35) 2018; 10
Blanden (10.1016/j.heliyon.2024.e26260_bib104) 2020; 9
Silva (10.1016/j.heliyon.2024.e26260_bib15) 2018; 51
Ory (10.1016/j.heliyon.2024.e26260_bib77) 1994; 13
Chen (10.1016/j.heliyon.2024.e26260_bib21) 2021; 21
Silva (10.1016/j.heliyon.2024.e26260_bib88) 2013; 33
Lubin (10.1016/j.heliyon.2024.e26260_bib90) 2010; 395
Prusiner (10.1016/j.heliyon.2024.e26260_bib64) 2012; 336
Milner (10.1016/j.heliyon.2024.e26260_bib65) 1995; 20
Ghosh (10.1016/j.heliyon.2024.e26260_bib116) 2014; 53
Duffy (10.1016/j.heliyon.2024.e26260_bib125) 2022; 14
Borrero (10.1016/j.heliyon.2024.e26260_bib27) 2021; 1876
Liu (10.1016/j.heliyon.2024.e26260_bib138) 2013; 41
Zoghbi (10.1016/j.heliyon.2024.e26260_bib196) 1995; vol. 6
Eisenberg (10.10
References_xml – volume: 5
  start-page: 8879
  year: 2014
  end-page: 8892
  ident: bib45
  article-title: Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism
  publication-title: Oncotarget
– volume: 86
  start-page: 27
  year: 2017
  end-page: 68
  ident: bib60
  article-title: Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade
  publication-title: Annu. Rev. Biochem.
– volume: 489
  start-page: 130
  year: 2017
  end-page: 134
  ident: bib154
  article-title: Polyarginine and its analogues inhibit p53 mutant aggregation and cancer cell proliferation in vitro
  publication-title: Biochem. Biophys. Res. Commun.
– volume: 11
  start-page: 2581
  year: 2012
  end-page: 2582
  ident: bib7
  article-title: p53 reactivation: the link to zinc
  publication-title: Cell Cycle
– volume: 33
  start-page: 527
  year: 2013
  end-page: 536
  ident: bib46
  article-title: The effect of zinc and the role of p53 in copper-induced cellular stress responses
  publication-title: J. Appl. Toxicol.
– volume: 11
  start-page: 4436
  year: 2012
  end-page: 4446
  ident: bib157
  article-title: Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy
  publication-title: Cell Cycle
– volume: 37
  start-page: 865
  year: 2016
  end-page: 876
  ident: bib50
  article-title: TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data
  publication-title: Hum. Mutat.
– volume: 14
  start-page: 157
  year: 2021
  ident: bib9
  article-title: Targeting mutant p53 for cancer therapy: direct and indirect strategies
  publication-title: J. Hematol. Oncol.
– volume: 42
  start-page: 9679
  year: 2013
  end-page: 9687
  ident: bib106
  article-title: Improving the bioactivity of Zn(II)-curcumin based complexes
  publication-title: Dalton Trans.
– volume: 46
  start-page: 6471
  year: 2019
  end-page: 6484
  ident: bib174
  article-title: Evaluation of the CRISPR/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3
  publication-title: Mol. Biol. Rep.
– volume: 10
  start-page: 1679
  year: 2011
  end-page: 1689
  ident: bib105
  article-title: Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs
  publication-title: Cell Cycle
– volume: 5
  start-page: 893
  year: 1990
  end-page: 899
  ident: bib81
  article-title: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines
  publication-title: Oncogene
– volume: 81
  start-page: 2507
  year: 2021
  end-page: 2519
  ident: bib26
  article-title: Maintenance of organellar protein homeostasis by ER-associated degradation and related mechanisms
  publication-title: Mol. Cell
– volume: 54
  start-page: 3752
  year: 1994
  end-page: 3757
  ident: bib73
  article-title: p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer
  publication-title: Cancer Res.
– volume: 16
  start-page: 543
  year: 2019
  end-page: 552
  ident: bib126
  article-title: PRIMA-1MET induces cellular senescence and apoptotic cell death in cholangiocarcinoma cells
  publication-title: Cancer Genom Proteom
– volume: 1
  start-page: 321
  year: 1992
  end-page: 327
  ident: bib190
  article-title: Mislocalization of ΔF508 CFTR in cystic fibrosis sweat gland
  publication-title: Nat. Genet.
– volume: 89
  start-page: 7262
  year: 1992
  end-page: 7266
  ident: bib82
  article-title: Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 22
  start-page: 127
  year: 2023
  end-page: 144
  ident: bib163
  article-title: Drugging p53 in cancer: one protein, many targets
  publication-title: Nat. Rev. Drug Discov.
– volume: 11
  start-page: 19264
  year: 2021
  ident: bib136
  article-title: Pathogenic genetic variants from highly connected cancer susceptibility genes confer the loss of structural stability
  publication-title: Sci. Rep.
– volume: 5
  start-page: 4202
  year: 2014
  ident: bib149
  article-title: Structure and mechanism of action of the hydroxy-aryl-aldehyde class of IRE1 endoribonuclease inhibitors
  publication-title: Nat. Commun.
– volume: 5
  start-page: 97
  year: 2015
  ident: bib12
  article-title: Misfolding, aggregation, and disordered segments in c-abl and p53 in human cancer
  publication-title: Front. Oncol.
– volume: 5
  start-page: 289
  year: 2015
  ident: bib137
  article-title: Mutant p53: one, No one, and one hundred thousand
  publication-title: Front. Oncol.
– volume: 10
  start-page: 154
  year: 2018
  ident: bib97
  article-title: Treating p53 mutant aggregation-associated cancer
  publication-title: Cancers
– volume: 37
  start-page: 174
  year: 2017
  end-page: 188
  ident: bib183
  article-title: Creutzfeldt‐jakob disease
  publication-title: Neuropathology
– volume: 21
  start-page: 71
  year: 2021
  end-page: 88
  ident: bib21
  article-title: Endoplasmic reticulum stress signals in the tumour and its microenvironment
  publication-title: Nat. Rev. Cancer
– volume: 15
  start-page: 67
  year: 2021
  end-page: 77
  ident: bib165
  article-title: The current status of gene therapy for the treatment of cancer
  publication-title: Biologics
– volume: 20
  start-page: 1226
  year: 2019
  end-page: 1245
  ident: bib57
  article-title: Protein misfolding diseases and therapeutic approaches
  publication-title: Curr. Protein Pept. Sci.
– volume: 10
  start-page: 3149
  year: 2021
  ident: bib118
  article-title: Redox sensitive cysteine residues as crucial regulators of wild-type and mutant p53 isoforms
  publication-title: Cells
– volume: 605
  start-page: 304
  year: 2022
  end-page: 309
  ident: bib55
  article-title: Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43
  publication-title: Nature
– volume: 26
  start-page: 1268
  year: 2012
  end-page: 1286
  ident: bib43
  article-title: Mutant p53: one name, many proteins
  publication-title: Genes Dev.
– volume: 20
  start-page: 49
  year: 1995
  end-page: 51
  ident: bib65
  article-title: Flexibility: the key to p53 function?
  publication-title: Trends Biochem. Sci.
– volume: 71
  start-page: 178
  year: 2018
  end-page: 190
  ident: bib41
  article-title: A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation
  publication-title: Mol. Cell
– volume: 23
  start-page: 11023
  year: 2022
  end-page: 12930
  ident: bib98
  article-title: Anticancer therapeutic strategies targeting p53 aggregation
  publication-title: Int. J. Mol. Sci.
– volume: 110
  start-page: E3445
  year: 2013
  end-page: E3454
  ident: bib155
  article-title: Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 10
  start-page: 5382
  year: 2019
  ident: bib164
  article-title: Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen
  publication-title: Nat. Commun.
– volume: 23
  start-page: 29
  year: 2021
  ident: bib156
  article-title: First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
  publication-title: Breast Cancer Res.
– volume: 16
  start-page: 460
  year: 1993
  end-page: 465
  ident: bib182
  article-title: Tau protein and the neurofibrillary pathology of Alzheimer's disease
  publication-title: Trends Neurosci.
– volume: 294
  start-page: 3670
  year: 2019
  end-page: 3682
  ident: bib122
  article-title: p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells
  publication-title: J. Biol. Chem.
– volume: vol. 79
  start-page: 58
  year: 2022
  end-page: 67
  ident: bib44
  publication-title: Semin Cancer Biol
– volume: 9
  start-page: 29112
  year: 2018
  ident: bib148
  article-title: Resveratrol prevents p53 aggregation in vitro and in breast cancer cells
  publication-title: Oncotarget
– volume: 27
  start-page: 739
  year: 1998
  end-page: 763
  ident: bib198
  article-title: Hypogonadotropic hypogonadism
  publication-title: Endocrinol Metab. Clin. N. Am.
– volume: 89
  start-page: 245
  year: 2008
  end-page: 260
  ident: bib181
  article-title: Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease
  publication-title: Handb. Clin. Neurol.
– volume: 2
  start-page: a000919
  year: 2010
  ident: bib121
  article-title: The tumor suppressor p53: from structures to drug discovery
  publication-title: Cold Spring Harbor Perspect. Biol.
– volume: 232
  start-page: 67
  year: 2003
  end-page: 76
  ident: bib202
  article-title: Aberrant protein folding as the molecular basis of cancer
  publication-title: Methods Mol. Biol.
– volume: 83
  start-page: 1
  year: 2019
  end-page: 15
  ident: bib31
  article-title: Awakening the “guardian of genome”: reactivation of mutant p53
  publication-title: Cancer Chemother. Pharmacol.
– volume: 24
  start-page: 2206
  year: 2013
  end-page: 2223
  ident: bib4
  article-title: Personalizing the treatment of women with early breast cancer: highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2013
  publication-title: Ann. Oncol.
– volume: 414
  start-page: 99
  year: 2018
  end-page: 106
  ident: bib133
  article-title: Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigation with the anti-p53 drug, PK11007
  publication-title: Cancer Lett.
– volume: 39
  start-page: 260
  year: 2014
  end-page: 267
  ident: bib13
  article-title: Prion-like aggregation of mutant p53 in cancer
  publication-title: Trends Biochem. Sci.
– volume: 14
  year: 2022
  ident: bib114
  article-title: Mutant p53 depletion by novel inhibitors for HSP40/J-domain proteins derived from the natural compound plumbagin
  publication-title: Cancers
– volume: 30
  start-page: 384
  year: 2020
  end-page: 398
  ident: bib22
  article-title: ER-phagy: quality control and turnover of endoplasmic reticulum
  publication-title: Trends Cell Biol.
– volume: 3
  start-page: 101
  year: 2007
  end-page: 107
  ident: bib201
  article-title: Structure of acid β-glucosidase with pharmacological chaperone provides insight into Gaucher disease
  publication-title: Nat. Chem. Biol.
– start-page: 2930
  year: 2017
  ident: bib131
  article-title: Combined treatment using the anti-p53 drug, APR-246 and eribulin: synergistic growth inhibition in p53-mutated breast cancer cells
  publication-title: J. Clin. Oncol.
– volume: 462
  start-page: 293
  year: 2000
  end-page: 301
  ident: bib70
  article-title: The yeast p53 functional assay: a new tool for molecular epidemiology. Hopes and facts
  publication-title: Mutat. Res.
– volume: 261
  start-page: 1227
  year: 2014
  end-page: 1233
  ident: bib194
  article-title: Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy
  publication-title: J. Neurol.
– volume: 10
  start-page: 288
  year: 2018
  ident: bib49
  article-title: p53 isoforms and their implications in cancer
  publication-title: Cancers
– volume: 77
  start-page: 266
  year: 2020
  end-page: 278
  ident: bib72
  article-title: Widespread prion-based control of growth and differentiation strategies in Saccharomyces cerevisiae
  publication-title: Mol. Cell
– volume: 197
  start-page: 857
  year: 2012
  end-page: 867
  ident: bib25
  article-title: The impact of the unfolded protein response on human disease
  publication-title: J. Cell Biol.
– volume: 7
  start-page: 69549
  year: 2016
  ident: bib68
  article-title: The dominant-negative interplay between p53, p63 and p73: a family affair
  publication-title: Oncotarget
– volume: 32
  start-page: 72
  year: 2013
  ident: bib107
  article-title: A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells
  publication-title: J. Exp. Clin. Cancer Res.
– year: 2019
  ident: bib166
  article-title: Encyclopedia of Tissue Engineering and Regenerative Medicine
– volume: 7
  start-page: 285
  year: 2011
  end-page: 295
  ident: bib92
  article-title: Gain of function of mutant p53 by coaggregation with multiple tumor suppressors
  publication-title: Nat. Chem. Biol.
– year: 2020
  ident: bib8
  article-title: Specific degradation of misfolded mutant p53 in cancer cells through the use of natural compounds targeting mutant p53 and DNAJA1 proteins
  publication-title: GME Research Days 2020; Research Days
– volume: 9
  start-page: 439
  year: 2018
  ident: bib123
  article-title: APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
  publication-title: Cell Death Dis.
– volume: 6
  start-page: 62
  year: 2020
  end-page: 73
  ident: bib39
  article-title: Mutant p53 on the path to metastasis
  publication-title: Trends Cancer
– volume: 162
  start-page: 1365
  year: 2010
  end-page: 1369
  ident: bib192
  article-title: Identification of novel and known KRT5 and KRT14 mutations in 53 patients with epidermolysis bullosa simplex: correlation between genotype and phenotype
  publication-title: Br. J. Dermatol.
– volume: 349
  year: 2015
  ident: bib32
  article-title: Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53
  publication-title: Science
– volume: 1876
  start-page: 188556
  year: 2021
  ident: bib27
  article-title: Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting
  publication-title: Biochim. Biophys. Acta Rev. Canc
– volume: 83
  start-page: 258
  year: 2017
  end-page: 265
  ident: bib101
  article-title: Mutant p53 as a target for cancer treatment
  publication-title: Eur. J. Cancer
– volume: 5
  start-page: 284
  year: 2015
  ident: bib119
  article-title: Regulation of mutant p53 protein expression
  publication-title: Front. Oncol.
– volume: 26
  start-page: 301
  year: 2022
  end-page: 308
  ident: bib180
  article-title: Hyperactivating p53 in human papillomavirus-driven cancers: a potential therapeutic intervention
  publication-title: Mol. Diagn. Ther.
– volume: 150
  year: 2019
  ident: bib69
  article-title: Yeast as a chassis for developing functional assays to study human P53
  publication-title: J. Vis. Exp.
– start-page: 2930
  year: 2020
  ident: bib94
  article-title: Dual modulators of p53 and Cyclin D in ER alpha signaling by albumin nanovectors bearing zinc chaperones for ER positive breast cancer therapy
  publication-title: Mini Rev. Med. Chem.
– volume: 295
  start-page: 2465
  year: 2002
  end-page: 2468
  ident: bib145
  article-title: Molecular determinants for the tissue specificity of SERMs
  publication-title: Science
– volume: 9
  start-page: e61487
  year: 2020
  end-page: e62930
  ident: bib104
  article-title: Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants
  publication-title: Elife
– volume: 140
  start-page: 234
  year: 2017
  end-page: 246
  ident: bib19
  article-title: Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
  publication-title: Int. J. Cancer
– volume: 24
  start-page: 3484
  year: 2005
  end-page: 3491
  ident: bib130
  article-title: PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
  publication-title: Oncogene
– volume: 9
  start-page: 402
  year: 2008
  end-page: 412
  ident: bib33
  article-title: Transcriptional control of human p53-regulated genes
  publication-title: Nat. Rev. Mol. Cell Biol.
– volume: 55
  start-page: 98
  year: 2016
  end-page: 110
  ident: bib128
  article-title: p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib
  publication-title: Eur. J. Cancer
– volume: 20
  start-page: 146
  year: 2004
  end-page: 154
  ident: bib184
  article-title: Huntingtin-protein interactions and the pathogenesis of Huntington's disease
  publication-title: Trends Genet.
– volume: 41
  start-page: 608
  year: 2012
  end-page: 621
  ident: bib53
  article-title: Misfolded proteins in Alzheimer's disease and type II diabetes
  publication-title: Chem. Soc. Rev.
– volume: 59
  start-page: 146
  year: 2020
  end-page: 155
  ident: bib17
  article-title: Prion-like p53 amyloids in cancer
  publication-title: Biochemistry
– volume: 17
  start-page: 829
  year: 2015
  end-page: 838
  ident: bib24
  article-title: Proteostasis control by the unfolded protein response
  publication-title: J.N.c.b.
– volume: 24
  start-page: 2930
  year: 2021
  ident: bib76
  article-title: Tumor suppressor protein p53 expressed in yeast can remain diffuse, form a prion, or form unstable liquid-like droplets
  publication-title: iScience
– volume: 29
  start-page: 938
  year: 2022
  end-page: 945
  ident: bib28
  article-title: The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein
  publication-title: Cell Death Differ.
– volume: 24
  start-page: 73
  year: 2010
  end-page: 79
  ident: bib95
  article-title: Implication of necrosis-linked p53 aggregation in acquired apoptotic resistance to 5-FU in MCF-7 multicellular tumour spheroids
  publication-title: Oncol. Rep.
– volume: 14
  start-page: 1215995
  year: 2023
  ident: bib113
  article-title: Targeting mutant p53 stabilization for cancer therapy
  publication-title: Front. Pharmacol.
– volume: 38
  start-page: 3415
  year: 2019
  end-page: 3427
  ident: bib171
  article-title: Cancer therapeutic targeting using mutant-p53-specific siRNAs
  publication-title: Oncogene
– volume: 86
  start-page: 69
  year: 2017
  end-page: 95
  ident: bib59
  article-title: Structural studies of amyloid proteins at the molecular level
  publication-title: Annu. Rev. Biochem.
– volume: 21
  start-page: 792
  year: 2021
  end-page: 802
  ident: bib110
  article-title: Dual modulators of p53 and Cyclin D in ER alpha signaling by albumin nanovectors bearing zinc chaperones for ER-positive breast cancer therapy
  publication-title: Mini Rev. Med. Chem.
– volume: 140
  start-page: 145
  year: 1992
  end-page: 153
  ident: bib83
  article-title: Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue
  publication-title: Am. J. Pathol.
– volume: 107
  start-page: 3487
  year: 2010
  end-page: 3492
  ident: bib152
  article-title: Identifying the amylome, proteins capable of forming amyloid-like fibrils
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 11
  start-page: 3513
  year: 1992
  end-page: 3520
  ident: bib79
  article-title: Interaction of heat-shock protein 70 with p53 translated in vitro: evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation
  publication-title: EMBO J.
– volume: 13
  start-page: 3496
  year: 1994
  end-page: 3504
  ident: bib77
  article-title: Analysis of the most representative tumour‐derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation
  publication-title: EMBO J.
– volume: 92
  start-page: 4407
  year: 1995
  end-page: 4411
  ident: bib75
  article-title: Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 75
  start-page: 397
  year: 1997
  end-page: 415
  ident: bib199
  article-title: α1-Antitrypsin deficiency: memorandum from a WHO meeting
  publication-title: Bull. World Health Organ.
– volume: 9
  start-page: 895887
  year: 2022
  ident: bib34
  article-title: p53 and zinc: a malleable relationship
  publication-title: Front. Mol. Biosci.
– volume: 1865
  start-page: 589
  year: 2017
  end-page: 603
  ident: bib146
  article-title: Polyphenols in combination with β-cyclodextrin can inhibit and disaggregate α-synuclein amyloids under cell mimicking conditions: a promising therapeutic alternative
  publication-title: Biochim. Biophys. Acta, Proteins Proteomics
– volume: 5
  start-page: 288
  year: 2015
  ident: bib124
  article-title: Targeting oncogenic mutant p53 for cancer therapy
  publication-title: Front. Oncol.
– volume: 7
  year: 2020
  ident: bib173
  article-title: Therapeutic applications of CRISPR/Cas9 in breast cancer and delivery potential of gold nanomaterials
  publication-title: Nanobiomedicine (Rij)
– volume: 162
  start-page: 452
  year: 1988
  end-page: 458
  ident: bib78
  article-title: Evidence that immunological variants of p53 represent alternative protein conformation
  publication-title: Virology
– volume: 1
  start-page: 779
  year: 2010
  end-page: 786
  ident: bib158
  article-title: The role of ubiquitin in autophagy-dependent protein aggregate processing
  publication-title: Genes Cancer
– volume: 72
  start-page: 102230
  year: 2023
  end-page: 102930
  ident: bib36
  article-title: Inhibition of p53 protein aggregation as a cancer treatment strategy
  publication-title: Curr. Opin. Chem. Biol.
– volume: 157
  start-page: 193
  year: 1989
  end-page: 199
  ident: bib80
  article-title: Expression of the nuclear oncogene p53 in colon tumours
  publication-title: J. Pathol.
– volume: 25
  start-page: 215
  year: 2018
  end-page: 219
  ident: bib84
  article-title: Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee
  publication-title: Amyloid
– volume: 368
  start-page: 756
  year: 1994
  end-page: 760
  ident: bib188
  article-title: Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus
  publication-title: Nature
– volume: 71
  start-page: 19
  year: 2018
  end-page: 31
  ident: bib6
  article-title: Restoring guardianship of the genome: anticancer drug strategies to reverse oncogenic mutant p53 misfolding
  publication-title: Cancer Treat Rev.
– volume: 9
  start-page: 4441
  year: 2018
  ident: bib177
  article-title: Structural dynamics of the E6AP/UBE3A-E6-p53 enzyme-substrate complex
  publication-title: Nat. Commun.
– volume: 18
  start-page: 89
  year: 2018
  end-page: 102
  ident: bib102
  article-title: Targeting mutant p53 for efficient cancer therapy
  publication-title: Nat. Rev. Cancer
– volume: 7
  start-page: 14458
  year: 2016
  end-page: 14475
  ident: bib142
  article-title: Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3
  publication-title: Oncotarget
– volume: 105
  start-page: 10360
  year: 2008
  end-page: 10365
  ident: bib140
  article-title: Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 10
  start-page: 595187
  year: 2020
  ident: bib42
  article-title: Mutant p53 in cancer progression and targeted therapies
  publication-title: Front. Oncol.
– volume: 77
  start-page: 251
  year: 2020
  end-page: 265
  ident: bib71
  article-title: A non-amyloid prion particle that activates a heritable gene expression program
  publication-title: Mol. Cell
– volume: 395
  start-page: 705
  year: 2010
  end-page: 716
  ident: bib90
  article-title: Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function
  publication-title: J. Mol. Biol.
– volume: 7
  start-page: 41363
  year: 2016
  end-page: 42930
  ident: bib135
  article-title: COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo
  publication-title: Oncotarget
– volume: 14
  start-page: 2850
  year: 2015
  end-page: 2863
  ident: bib143
  article-title: Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator nutlin-3a in a humanized orthotopic breast-to-lung metastatic ModelModulation of Mdm2 in the context of DNA damage
  publication-title: Mol. Cancer Therapeut.
– volume: 22
  start-page: 61
  year: 2020
  ident: bib5
  article-title: Triple-negative breast cancer molecular subtyping and treatment progress
  publication-title: Breast Cancer Res.
– volume: 20
  start-page: 199
  year: 2019
  end-page: 210
  ident: bib30
  article-title: The multiple mechanisms that regulate p53 activity and cell fate
  publication-title: Nat. Rev. Mol. Cell Biol.
– volume: 10
  start-page: 303
  year: 2020
  ident: bib103
  article-title: Follow the mutations: toward class-specific, small-molecule reactivation of p53
  publication-title: Biomolecules
– volume: 18
  start-page: 246
  year: 2010
  end-page: 256
  ident: bib48
  article-title: Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer
  publication-title: Structure
– volume: 25
  start-page: 1219
  year: 2018
  end-page: 1230
  ident: bib117
  article-title: Role of thiol reactivity for targeting mutant p53
  publication-title: Cell Chem. Biol.
– volume: 11
  start-page: 460
  year: 2020
  ident: bib160
  article-title: Mitochondrial dysfunction generates aggregates that resist lysosomal degradation in human breast cancer cells
  publication-title: Cell Death Dis.
– volume: 10
  start-page: 166
  year: 2018
  ident: bib35
  article-title: Zinc metallochaperones as mutant p53 reactivators: a new paradigm in cancer therapeutics
  publication-title: Cancers
– volume: 53
  start-page: 5995
  year: 2014
  end-page: 6010
  ident: bib116
  article-title: Investigating the intrinsic aggregation potential of evolutionarily conserved segments in p53
  publication-title: Biochemistry
– volume: 99
  start-page: 14849
  year: 2002
  end-page: 14854
  ident: bib170
  article-title: Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 24
  start-page: 1784
  year: 2017
  end-page: 1798
  ident: bib14
  article-title: p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis
  publication-title: Cell Death Differ.
– volume: 86
  start-page: 109
  year: 2008
  end-page: 127
  ident: bib185
  article-title: A review of Parkinson's disease
  publication-title: Br. Med. Bull.
– volume: 10
  start-page: 188
  year: 2018
  ident: bib40
  article-title: Gain-of-function (GOF) mutant p53 as actionable therapeutic target
  publication-title: Cancers
– volume: 6
  start-page: 32535
  year: 2016
  end-page: 32930
  ident: bib115
  article-title: Aggregation tendencies in the p53 family are modulated by backbone hydrogen bonds
  publication-title: Sci. Rep.
– volume: 170
  start-page: 213
  year: 2018
  end-page: 219
  ident: bib20
  article-title: Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
  publication-title: Breast Cancer Res. Treat.
– volume: 80
  year: 2020
  ident: bib111
  article-title: Zinc metallochaperones for mutant p53 reactivation in cancer therapeutics
  publication-title: Cancer Res.
– volume: 292
  start-page: 9345
  year: 2017
  end-page: 9357
  ident: bib16
  article-title: Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain
  publication-title: J. Biol. Chem.
– volume: 16
  start-page: 156
  year: 1997
  end-page: 162
  ident: bib74
  article-title: Role of p53 alteration in primary peritoneal carcinoma
  publication-title: Int. J. Gynecol. Pathol.
– volume: 23
  start-page: 209
  year: 2016
  end-page: 213
  ident: bib85
  article-title: Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines
  publication-title: Amyloid
– volume: 8
  start-page: 75
  year: 2014
  end-page: 84
  ident: bib99
  article-title: The aggregation of mutant p53 produces prion-like properties in cancer
  publication-title: Prion
– volume: 21
  start-page: 614
  year: 2012
  end-page: 625
  ident: bib109
  article-title: Allele-specific p53 mutant reactivation
  publication-title: Cancer Cell
– volume: 125
  start-page: 407
  year: 2011
  end-page: 420
  ident: bib129
  article-title: Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors
  publication-title: Breast Cancer Res. Treat.
– volume: 9
  start-page: 172
  year: 2017
  ident: bib127
  article-title: PRIMA-1 and PRIMA-1Met (APR-246): from mutant/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies
  publication-title: Cancers
– volume: 6
  start-page: 55
  year: 2017
  end-page: 61
  ident: bib186
  article-title: Oxidative alterations in sickle cell disease: possible involvement in disease pathogenesis
  publication-title: World J. Hematol.
– volume: 6
  start-page: 78
  year: 2020
  ident: bib193
  article-title: Epidermolysis bullosa
  publication-title: Nat. Rev. Dis. Prim.
– volume: 15
  start-page: 657
  year: 2020
  end-page: 668
  ident: bib139
  article-title: Targeting cavity-creating p53 cancer mutations with small-molecule stabilizers: the Y220X paradigm
  publication-title: ACS Chem. Biol.
– volume: 428
  start-page: 319
  year: 2004
  end-page: 323
  ident: bib62
  article-title: Protein-only transmission of three yeast prion strains
  publication-title: Nature
– volume: 109
  start-page: 13584
  year: 2012
  end-page: 13589
  ident: bib89
  article-title: Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 113
  start-page: E5271
  year: 2016
  end-page: E5280
  ident: bib132
  article-title: 2-Sulfonylpyrimidines: mild alkylating agents with anticancer activity toward p53-compromised cells
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 68
  start-page: 6708
  year: 2008
  end-page: 6717
  ident: bib141
  article-title: Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress
  publication-title: Cancer Res.
– volume: 43
  start-page: 60
  year: 2011
  end-page: 64
  ident: bib18
  article-title: Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors
  publication-title: Int. J. Biochem. Cell Biol.
– volume: 21
  year: 2020
  ident: bib3
  article-title: Effect of CD44 aptamer on snail metastasis factor and aggressiveness of MDA-MB-231 breast cancer cell line
  publication-title: Shiraz E Med. J.
– volume: 381
  start-page: 61
  year: 2013
  end-page: 68
  ident: bib172
  article-title: p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells
  publication-title: Mol. Cell. Biochem.
– volume: 10
  start-page: 607149
  year: 2021
  ident: bib159
  article-title: Mutant p53 as a regulator and target of autophagy
  publication-title: Front. Oncol.
– volume: vol. 6
  start-page: 29
  year: 1995
  end-page: 35
  ident: bib196
  publication-title: Semin Cell Biol
– volume: 170
  start-page: 1062
  year: 2017
  end-page: 1078
  ident: bib10
  article-title: Putting p53 in context
  publication-title: Cell
– volume: 29
  start-page: 90
  year: 2016
  end-page: 103
  ident: bib151
  article-title: A designed inhibitor of p53 aggregation rescues p53 tumor suppression in ovarian carcinomas
  publication-title: Cancer Cell
– volume: 21
  start-page: 792
  year: 2021
  end-page: 802
  ident: bib93
  article-title: Dual modulators of p53 and Cyclin D in ER alpha signaling by albumin nanovectors bearing zinc chaperones for ER-positive breast cancer therapy
  publication-title: Mini Rev. Med. Chem.
– volume: 35
  start-page: 1334
  year: 2014
  end-page: 1346
  ident: bib168
  article-title: A cationic cholesterol based nanocarrier for the delivery of p53-EGFP-C3 plasmid to cancer cells
  publication-title: Biomaterials
– volume: 533
  start-page: 420
  year: 2016
  end-page: 424
  ident: bib175
  article-title: Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
  publication-title: Nature
– volume: 8
  start-page: a023614
  year: 2016
  ident: bib11
  article-title: Aggregation and prion-like properties of misfolded tumor suppressors: is cancer a prion disease?
  publication-title: Cold Spring Harbor Perspect. Biol.
– volume: 11
  start-page: 330
  year: 2019
  end-page: 341
  ident: bib37
  article-title: p53 as a hub in cellular redox regulation and therapeutic target in cancer
  publication-title: J. Mol. Cell Biol.
– volume: 290
  start-page: 29769
  year: 2015
  end-page: 29780
  ident: bib147
  article-title: Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites
  publication-title: J. Biol. Chem.
– volume: 13
  start-page: 3676
  year: 2017
  end-page: 3680
  ident: bib179
  article-title: Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: a clinical trial
  publication-title: Oncol. Lett.
– volume: 33
  start-page: 132
  year: 2008
  end-page: 140
  ident: bib86
  article-title: Intriguing nucleic-acid-binding features of mammalian prion protein
  publication-title: Trends Biochem. Sci.
– volume: 33
  year: 2013
  ident: bib88
  article-title: Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor
  publication-title: Biosci. Rep.
– volume: 41
  start-page: 6034
  year: 2013
  end-page: 6044
  ident: bib138
  article-title: Small molecule induced reactivation of mutant p53 in cancer cells
  publication-title: Nucleic Acids Res.
– volume: 28
  start-page: 639
  year: 2017
  end-page: 653
  ident: bib167
  article-title: Induction of oxidants distinguishes susceptibility of prostate carcinoma cell lines to p53 gene transfer mediated by an improved adenoviral vector
  publication-title: Hum. Gene Ther.
– volume: 352
  start-page: 77
  year: 1991
  end-page: 79
  ident: bib191
  article-title: Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
  publication-title: Nature
– volume: 9
  start-page: 3267
  year: 2018
  ident: bib150
  article-title: Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy
  publication-title: Nat. Commun.
– volume: 23
  start-page: 101
  year: 2016
  end-page: 110
  ident: bib169
  article-title: p53 gene therapy of human breast carcinoma: using a transferrin-modified silica nanoparticles
  publication-title: Breast Cancer
– volume: 4
  start-page: 522
  year: 2016
  ident: bib38
  article-title: P53 mutations and cancer: a tight linkage
  publication-title: Ann. Transl. Med.
– volume: 88
  start-page: 1084
  year: 2015
  ident: bib108
  article-title: Erratum: synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore (Molecular Pharmacology (2015) 87 (825-831))
  publication-title: Mol. Pharmacol.
– volume: 77
  start-page: 2699
  year: 2017
  end-page: 2711
  ident: bib162
  article-title: Development of a T-cell receptor mimic antibody against wild-type p53 for cancer ImmunotherapyTCR mimic antibody against p53 for cancer immunotherapy
  publication-title: Cancer Res.
– volume: 29
  start-page: 160
  year: 2018
  end-page: 179
  ident: bib178
  article-title: The first approved gene therapy product for cancer ad-p53 (gendicine): 12 Years in the clinic
  publication-title: Hum. Gene Ther.
– volume: 36
  start-page: 5473
  year: 2017
  end-page: 5483
  ident: bib153
  article-title: Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp
  publication-title: Oncogene
– volume: 15
  start-page: 384
  year: 2014
  end-page: 396
  ident: bib61
  article-title: The amyloid state and its association with protein misfolding diseases
  publication-title: Nat. Rev. Mol. Cell Biol.
– volume: 16
  start-page: 48
  year: 1996
  end-page: 55
  ident: bib197
  article-title: Neuropathology of dentatorubropallidoluysian atrophy
  publication-title: Neuropathology
– volume: 11
  start-page: a033928
  year: 2019
  ident: bib23
  article-title: Chaperoning endoplasmic reticulum-associated degradation (ERAD) and protein conformational diseases
  publication-title: Cold Spring Harbor Perspect. Biol.
– volume: 51
  start-page: 181
  year: 2018
  end-page: 190
  ident: bib15
  article-title: Targeting the prion-like aggregation of mutant p53 to combat cancer
  publication-title: Acc. Chem. Res.
– volume: 24
  start-page: 927
  year: 2018
  end-page: 930
  ident: bib176
  article-title: CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response
  publication-title: Nat. Med.
– volume: 18
  start-page: 1233
  year: 2016
  end-page: 1243
  ident: bib112
  article-title: DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway
  publication-title: Nat. Cell Biol.
– volume: 109
  start-page: 13590
  year: 2012
  end-page: 13595
  ident: bib47
  article-title: First-order rate-determining aggregation mechanism of p53 and its implications
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 10
  start-page: 548
  year: 2020
  ident: bib52
  article-title: The status of p53 oligomeric and aggregation states in cancer
  publication-title: Biomolecules
– volume: 428
  start-page: 323
  year: 2004
  end-page: 328
  ident: bib63
  article-title: Conformational variations in an infectious protein determine prion strain differences
  publication-title: Nature
– volume: 65
  start-page: 765
  year: 1991
  end-page: 774
  ident: bib66
  article-title: Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation
  publication-title: Cell
– volume: 11
  start-page: 808
  year: 2021
  ident: bib1
  article-title: Breast cancer treatments: updates and new challenges
  publication-title: J. Personalized Med.
– volume: 34
  start-page: 382
  year: 2021
  end-page: 391
  ident: bib2
  article-title: Clinical values of two estrogen receptor signaling targeted lncRNAs in invasive ductal breast carcinoma
  publication-title: Klin. Onkol.
– volume: 336
  start-page: 1511
  year: 2012
  end-page: 1513
  ident: bib64
  article-title: Cell biology. A unifying role for prions in neurodegenerative diseases
  publication-title: Science
– volume: 43
  start-page: 271
  year: 2010
  end-page: 279
  ident: bib87
  article-title: Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins
  publication-title: Acc. Chem. Res.
– volume: 35
  year: 2017
  ident: bib134
  article-title: Targeting mutant p53 with PK11007: a new approach for the treatment of patients with triple-negative breast cancer?
  publication-title: J. Clin. Oncol.
– volume: 148
  start-page: 1188
  year: 2012
  end-page: 1203
  ident: bib54
  article-title: The amyloid state of proteins in human diseases
  publication-title: Cell
– volume: 114
  start-page: E2634
  year: 2017
  end-page: E2643
  ident: bib96
  article-title: Multisite aggregation of p53 and implications for drug rescue
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 326
  start-page: 444
  year: 1992
  end-page: 449
  ident: bib203
  article-title: Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene
  publication-title: N. Engl. J. Med.
– volume: 106
  start-page: 598
  year: 2016
  end-page: 612
  ident: bib29
  article-title: Tetramer formation of tumor suppressor protein p53: structure, function, and applications
  publication-title: Biopolymers
– volume: 285
  start-page: 2857
  year: 2010
  end-page: 2866
  ident: bib58
  article-title: The p53 core domain is a molten globule at low pH: functional implications of a partially unfolded structure
  publication-title: J. Biol. Chem.
– volume: 362
  start-page: 59
  year: 1993
  end-page: 62
  ident: bib195
  article-title: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
  publication-title: Nature
– volume: 21
  start-page: 1332
  year: 2018
  end-page: 1340
  ident: bib56
  article-title: Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases
  publication-title: Nat. Neurosci.
– volume: 372
  start-page: 1427
  year: 2008
  end-page: 1435
  ident: bib189
  article-title: Fabry's disease
  publication-title: Lancet
– volume: 23
  start-page: 1615
  year: 2016
  end-page: 1627
  ident: bib161
  article-title: Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth
  publication-title: Cell Death Differ.
– volume: 277
  start-page: 228
  year: 1997
  end-page: 231
  ident: bib200
  article-title: Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis
  publication-title: Science
– volume: 287
  start-page: 28152
  year: 2012
  end-page: 28162
  ident: bib51
  article-title: Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer
  publication-title: J. Biol. Chem.
– volume: 15
  start-page: 13
  year: 2018
  end-page: 30
  ident: bib100
  article-title: Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
  publication-title: Nat. Rev. Clin. Oncol.
– volume: 13
  start-page: 269
  year: 2021
  ident: bib67
  article-title: p53, A victim of the prion fashion
  publication-title: Cancers
– volume: 14
  start-page: 4499
  year: 2022
  ident: bib125
  article-title: Targeting mutant p53 for cancer treatment: moving closer to clinical use?
  publication-title: Cancers
– volume: 23
  start-page: 4883
  year: 2022
  ident: bib187
  article-title: Retinitis pigmentosa: progress in molecular pathology and biotherapeutical strategies
  publication-title: Int. J. Mol. Sci.
– volume: 8
  start-page: 8921
  year: 2017
  end-page: 8946
  ident: bib144
  article-title: The role of p53 in cancer drug resistance and targeted chemotherapy
  publication-title: Oncotarget
– volume: 15
  start-page: 2
  year: 2013
  end-page: 8
  ident: bib91
  article-title: p53 mutations in cancer
  publication-title: Nat. Cell Biol.
– volume: 278
  start-page: 24108
  year: 2003
  end-page: 24112
  ident: bib120
  article-title: Kinetic instability of p53 core domain mutants: implications for rescue by small molecules
  publication-title: J. Biol. Chem.
– volume: 295
  start-page: 2465
  issue: 5564
  year: 2002
  ident: 10.1016/j.heliyon.2024.e26260_bib145
  article-title: Molecular determinants for the tissue specificity of SERMs
  publication-title: Science
  doi: 10.1126/science.1068537
– volume: 7
  start-page: 14458
  issue: 12
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib142
  article-title: Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7363
– volume: 6
  start-page: 62
  issue: 1
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib39
  article-title: Mutant p53 on the path to metastasis
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2019.11.004
– volume: 106
  start-page: 598
  issue: 4
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib29
  article-title: Tetramer formation of tumor suppressor protein p53: structure, function, and applications
  publication-title: Biopolymers
  doi: 10.1002/bip.22772
– volume: 17
  start-page: 829
  issue: 7
  year: 2015
  ident: 10.1016/j.heliyon.2024.e26260_bib24
  article-title: Proteostasis control by the unfolded protein response
  publication-title: J.N.c.b.
– volume: 65
  start-page: 765
  issue: 5
  year: 1991
  ident: 10.1016/j.heliyon.2024.e26260_bib66
  article-title: Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation
  publication-title: Cell
  doi: 10.1016/0092-8674(91)90384-B
– volume: 5
  start-page: 893
  issue: 6
  year: 1990
  ident: 10.1016/j.heliyon.2024.e26260_bib81
  article-title: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines
  publication-title: Oncogene
– volume: 326
  start-page: 444
  issue: 7
  year: 1992
  ident: 10.1016/j.heliyon.2024.e26260_bib203
  article-title: Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM199202133260704
– volume: 5
  start-page: 97
  year: 2015
  ident: 10.1016/j.heliyon.2024.e26260_bib12
  article-title: Misfolding, aggregation, and disordered segments in c-abl and p53 in human cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2015.00097
– volume: 3
  start-page: 101
  issue: 2
  year: 2007
  ident: 10.1016/j.heliyon.2024.e26260_bib201
  article-title: Structure of acid β-glucosidase with pharmacological chaperone provides insight into Gaucher disease
  publication-title: Nat. Chem. Biol.
  doi: 10.1038/nchembio850
– volume: 1865
  start-page: 589
  issue: 5
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib146
  article-title: Polyphenols in combination with β-cyclodextrin can inhibit and disaggregate α-synuclein amyloids under cell mimicking conditions: a promising therapeutic alternative
  publication-title: Biochim. Biophys. Acta, Proteins Proteomics
  doi: 10.1016/j.bbapap.2017.02.014
– volume: 29
  start-page: 90
  issue: 1
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib151
  article-title: A designed inhibitor of p53 aggregation rescues p53 tumor suppression in ovarian carcinomas
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2015.12.002
– volume: 15
  start-page: 13
  issue: 1
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib100
  article-title: Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2017.151
– volume: 83
  start-page: 1
  year: 2019
  ident: 10.1016/j.heliyon.2024.e26260_bib31
  article-title: Awakening the “guardian of genome”: reactivation of mutant p53
  publication-title: Cancer Chemother. Pharmacol.
  doi: 10.1007/s00280-018-3701-x
– volume: 4
  start-page: 522
  issue: 24
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib38
  article-title: P53 mutations and cancer: a tight linkage
  publication-title: Ann. Transl. Med.
  doi: 10.21037/atm.2016.12.40
– volume: 8
  start-page: 8921
  issue: 5
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib144
  article-title: The role of p53 in cancer drug resistance and targeted chemotherapy
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13475
– volume: 34
  start-page: 382
  issue: 5
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib2
  article-title: Clinical values of two estrogen receptor signaling targeted lncRNAs in invasive ductal breast carcinoma
  publication-title: Klin. Onkol.
  doi: 10.48095/ccko2021382
– volume: 99
  start-page: 14849
  issue: 23
  year: 2002
  ident: 10.1016/j.heliyon.2024.e26260_bib170
  article-title: Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.222406899
– volume: 114
  start-page: E2634
  issue: 13
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib96
  article-title: Multisite aggregation of p53 and implications for drug rescue
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1700308114
– volume: 10
  start-page: 607149
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib159
  article-title: Mutant p53 as a regulator and target of autophagy
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.607149
– volume: 140
  start-page: 145
  issue: 1
  year: 1992
  ident: 10.1016/j.heliyon.2024.e26260_bib83
  article-title: Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue
  publication-title: Am. J. Pathol.
– volume: 88
  start-page: 1084
  issue: 6
  year: 2015
  ident: 10.1016/j.heliyon.2024.e26260_bib108
  article-title: Erratum: synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore (Molecular Pharmacology (2015) 87 (825-831))
  publication-title: Mol. Pharmacol.
  doi: 10.1124/mol.115.097550err
– volume: 18
  start-page: 246
  issue: 2
  year: 2010
  ident: 10.1016/j.heliyon.2024.e26260_bib48
  article-title: Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer
  publication-title: Structure
  doi: 10.1016/j.str.2009.11.011
– volume: 232
  start-page: 67
  year: 2003
  ident: 10.1016/j.heliyon.2024.e26260_bib202
  article-title: Aberrant protein folding as the molecular basis of cancer
  publication-title: Methods Mol. Biol.
– volume: 5
  start-page: 288
  year: 2015
  ident: 10.1016/j.heliyon.2024.e26260_bib124
  article-title: Targeting oncogenic mutant p53 for cancer therapy
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2015.00288
– volume: 24
  start-page: 2930
  issue: 1
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib76
  article-title: Tumor suppressor protein p53 expressed in yeast can remain diffuse, form a prion, or form unstable liquid-like droplets
  publication-title: iScience
  doi: 10.1016/j.isci.2020.102000
– volume: 1876
  start-page: 188556
  issue: 1
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib27
  article-title: Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting
  publication-title: Biochim. Biophys. Acta Rev. Canc
  doi: 10.1016/j.bbcan.2021.188556
– volume: 16
  start-page: 543
  issue: 6
  year: 2019
  ident: 10.1016/j.heliyon.2024.e26260_bib126
  article-title: PRIMA-1MET induces cellular senescence and apoptotic cell death in cholangiocarcinoma cells
  publication-title: Cancer Genom Proteom
  doi: 10.21873/cgp.20156
– volume: 24
  start-page: 3484
  issue: 21
  year: 2005
  ident: 10.1016/j.heliyon.2024.e26260_bib130
  article-title: PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1208419
– volume: 16
  start-page: 156
  issue: 2
  year: 1997
  ident: 10.1016/j.heliyon.2024.e26260_bib74
  article-title: Role of p53 alteration in primary peritoneal carcinoma
  publication-title: Int. J. Gynecol. Pathol.
  doi: 10.1097/00004347-199704000-00012
– volume: 24
  start-page: 1784
  issue: 10
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib14
  article-title: p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis
  publication-title: Cell Death Differ.
  doi: 10.1038/cdd.2017.105
– volume: 10
  start-page: 3149
  issue: 11
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib118
  article-title: Redox sensitive cysteine residues as crucial regulators of wild-type and mutant p53 isoforms
  publication-title: Cells
  doi: 10.3390/cells10113149
– volume: 362
  start-page: 59
  issue: 6415
  year: 1993
  ident: 10.1016/j.heliyon.2024.e26260_bib195
  article-title: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
  publication-title: Nature
  doi: 10.1038/362059a0
– volume: 5
  start-page: 4202
  issue: 1
  year: 2014
  ident: 10.1016/j.heliyon.2024.e26260_bib149
  article-title: Structure and mechanism of action of the hydroxy-aryl-aldehyde class of IRE1 endoribonuclease inhibitors
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms5202
– volume: 14
  start-page: 4499
  issue: 18
  year: 2022
  ident: 10.1016/j.heliyon.2024.e26260_bib125
  article-title: Targeting mutant p53 for cancer treatment: moving closer to clinical use?
  publication-title: Cancers
  doi: 10.3390/cancers14184499
– volume: 2
  start-page: a000919
  issue: 6
  year: 2010
  ident: 10.1016/j.heliyon.2024.e26260_bib121
  article-title: The tumor suppressor p53: from structures to drug discovery
  publication-title: Cold Spring Harbor Perspect. Biol.
  doi: 10.1101/cshperspect.a000919
– volume: 372
  start-page: 1427
  issue: 9647
  year: 2008
  ident: 10.1016/j.heliyon.2024.e26260_bib189
  article-title: Fabry's disease
  publication-title: Lancet
  doi: 10.1016/S0140-6736(08)61589-5
– volume: 287
  start-page: 28152
  issue: 33
  year: 2012
  ident: 10.1016/j.heliyon.2024.e26260_bib51
  article-title: Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M112.340638
– volume: 105
  start-page: 10360
  issue: 30
  year: 2008
  ident: 10.1016/j.heliyon.2024.e26260_bib140
  article-title: Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.0805326105
– volume: 43
  start-page: 60
  issue: 1
  year: 2011
  ident: 10.1016/j.heliyon.2024.e26260_bib18
  article-title: Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors
  publication-title: Int. J. Biochem. Cell Biol.
  doi: 10.1016/j.biocel.2010.10.017
– volume: 336
  start-page: 1511
  issue: 6088
  year: 2012
  ident: 10.1016/j.heliyon.2024.e26260_bib64
  article-title: Cell biology. A unifying role for prions in neurodegenerative diseases
  publication-title: Science
  doi: 10.1126/science.1222951
– volume: 16
  start-page: 460
  issue: 11
  year: 1993
  ident: 10.1016/j.heliyon.2024.e26260_bib182
  article-title: Tau protein and the neurofibrillary pathology of Alzheimer's disease
  publication-title: Trends Neurosci.
  doi: 10.1016/0166-2236(93)90078-Z
– volume: 21
  start-page: 1332
  issue: 10
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib56
  article-title: Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases
  publication-title: Nat. Neurosci.
  doi: 10.1038/s41593-018-0235-9
– volume: 10
  start-page: 1679
  issue: 10
  year: 2011
  ident: 10.1016/j.heliyon.2024.e26260_bib105
  article-title: Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs
  publication-title: Cell Cycle
  doi: 10.4161/cc.10.10.15642
– volume: 107
  start-page: 3487
  issue: 8
  year: 2010
  ident: 10.1016/j.heliyon.2024.e26260_bib152
  article-title: Identifying the amylome, proteins capable of forming amyloid-like fibrils
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.0915166107
– volume: 23
  start-page: 209
  issue: 4
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib85
  article-title: Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines
  publication-title: Amyloid
  doi: 10.1080/13506129.2016.1257986
– volume: 9
  start-page: 29112
  issue: 49
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib148
  article-title: Resveratrol prevents p53 aggregation in vitro and in breast cancer cells
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.25631
– volume: 21
  start-page: 792
  issue: 7
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib93
  article-title: Dual modulators of p53 and Cyclin D in ER alpha signaling by albumin nanovectors bearing zinc chaperones for ER-positive breast cancer therapy
  publication-title: Mini Rev. Med. Chem.
  doi: 10.2174/1389557520999201124212347
– volume: 11
  start-page: 3513
  issue: 10
  year: 1992
  ident: 10.1016/j.heliyon.2024.e26260_bib79
  article-title: Interaction of heat-shock protein 70 with p53 translated in vitro: evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation
  publication-title: EMBO J.
  doi: 10.1002/j.1460-2075.1992.tb05434.x
– volume: 157
  start-page: 193
  issue: 3
  year: 1989
  ident: 10.1016/j.heliyon.2024.e26260_bib80
  article-title: Expression of the nuclear oncogene p53 in colon tumours
  publication-title: J. Pathol.
  doi: 10.1002/path.1711570304
– volume: 89
  start-page: 245
  year: 2008
  ident: 10.1016/j.heliyon.2024.e26260_bib181
  article-title: Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease
  publication-title: Handb. Clin. Neurol.
  doi: 10.1016/S0072-9752(07)01223-7
– volume: 5
  start-page: 284
  year: 2015
  ident: 10.1016/j.heliyon.2024.e26260_bib119
  article-title: Regulation of mutant p53 protein expression
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2015.00284
– volume: 41
  start-page: 6034
  issue: 12
  year: 2013
  ident: 10.1016/j.heliyon.2024.e26260_bib138
  article-title: Small molecule induced reactivation of mutant p53 in cancer cells
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkt305
– volume: 8
  start-page: a023614
  issue: 10
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib11
  article-title: Aggregation and prion-like properties of misfolded tumor suppressors: is cancer a prion disease?
  publication-title: Cold Spring Harbor Perspect. Biol.
  doi: 10.1101/cshperspect.a023614
– volume: 292
  start-page: 9345
  issue: 22
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib16
  article-title: Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M116.762096
– volume: 6
  start-page: 32535
  issue: 1
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib115
  article-title: Aggregation tendencies in the p53 family are modulated by backbone hydrogen bonds
  publication-title: Sci. Rep.
  doi: 10.1038/srep32535
– volume: 9
  start-page: 895887
  year: 2022
  ident: 10.1016/j.heliyon.2024.e26260_bib34
  article-title: p53 and zinc: a malleable relationship
  publication-title: Front. Mol. Biosci.
  doi: 10.3389/fmolb.2022.895887
– volume: 15
  start-page: 2
  issue: 1
  year: 2013
  ident: 10.1016/j.heliyon.2024.e26260_bib91
  article-title: p53 mutations in cancer
  publication-title: Nat. Cell Biol.
  doi: 10.1038/ncb2641
– volume: 21
  start-page: 614
  issue: 5
  year: 2012
  ident: 10.1016/j.heliyon.2024.e26260_bib109
  article-title: Allele-specific p53 mutant reactivation
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2012.03.042
– volume: 80
  issue: 16_Supplement
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib111
  article-title: Zinc metallochaperones for mutant p53 reactivation in cancer therapeutics
  publication-title: Cancer Res.
  doi: 10.1158/1538-7445.AM2020-3432
– volume: 41
  start-page: 608
  issue: 2
  year: 2012
  ident: 10.1016/j.heliyon.2024.e26260_bib53
  article-title: Misfolded proteins in Alzheimer's disease and type II diabetes
  publication-title: Chem. Soc. Rev.
  doi: 10.1039/C1CS15112F
– volume: 489
  start-page: 130
  issue: 2
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib154
  article-title: Polyarginine and its analogues inhibit p53 mutant aggregation and cancer cell proliferation in vitro
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2017.05.111
– volume: 35
  issue: 15_suppl
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib134
  article-title: Targeting mutant p53 with PK11007: a new approach for the treatment of patients with triple-negative breast cancer?
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.35.15_suppl.e14099
– volume: 10
  start-page: 595187
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib42
  article-title: Mutant p53 in cancer progression and targeted therapies
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.595187
– volume: 109
  start-page: 13590
  issue: 34
  year: 2012
  ident: 10.1016/j.heliyon.2024.e26260_bib47
  article-title: First-order rate-determining aggregation mechanism of p53 and its implications
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1211557109
– volume: 54
  start-page: 3752
  issue: 14
  year: 1994
  ident: 10.1016/j.heliyon.2024.e26260_bib73
  article-title: p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer
  publication-title: Cancer Res.
– volume: 16
  start-page: 48
  issue: 1
  year: 1996
  ident: 10.1016/j.heliyon.2024.e26260_bib197
  article-title: Neuropathology of dentatorubropallidoluysian atrophy
  publication-title: Neuropathology
  doi: 10.1111/j.1440-1789.1996.tb00155.x
– volume: 349
  issue: 6247
  year: 2015
  ident: 10.1016/j.heliyon.2024.e26260_bib32
  article-title: Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53
  publication-title: Science
  doi: 10.1126/science.1261669
– volume: 11
  start-page: 808
  issue: 8
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib1
  article-title: Breast cancer treatments: updates and new challenges
  publication-title: J. Personalized Med.
  doi: 10.3390/jpm11080808
– volume: 38
  start-page: 3415
  issue: 18
  year: 2019
  ident: 10.1016/j.heliyon.2024.e26260_bib171
  article-title: Cancer therapeutic targeting using mutant-p53-specific siRNAs
  publication-title: Oncogene
  doi: 10.1038/s41388-018-0652-y
– volume: 10
  start-page: 154
  issue: 6
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib97
  article-title: Treating p53 mutant aggregation-associated cancer
  publication-title: Cancers
  doi: 10.3390/cancers10060154
– volume: 9
  start-page: e61487
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib104
  article-title: Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants
  publication-title: Elife
  doi: 10.7554/eLife.61487
– volume: 261
  start-page: 1227
  issue: 6
  year: 2014
  ident: 10.1016/j.heliyon.2024.e26260_bib194
  article-title: Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy
  publication-title: J. Neurol.
  doi: 10.1007/s00415-014-7373-0
– volume: 368
  start-page: 756
  issue: 6473
  year: 1994
  ident: 10.1016/j.heliyon.2024.e26260_bib188
  article-title: Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus
  publication-title: Nature
  doi: 10.1038/368756a0
– volume: 10
  start-page: 166
  issue: 6
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib35
  article-title: Zinc metallochaperones as mutant p53 reactivators: a new paradigm in cancer therapeutics
  publication-title: Cancers
  doi: 10.3390/cancers10060166
– volume: 9
  start-page: 4441
  issue: 1
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib177
  article-title: Structural dynamics of the E6AP/UBE3A-E6-p53 enzyme-substrate complex
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-06953-0
– volume: 75
  start-page: 397
  year: 1997
  ident: 10.1016/j.heliyon.2024.e26260_bib199
  article-title: α1-Antitrypsin deficiency: memorandum from a WHO meeting
  publication-title: Bull. World Health Organ.
– volume: 89
  start-page: 7262
  issue: 15
  year: 1992
  ident: 10.1016/j.heliyon.2024.e26260_bib82
  article-title: Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.89.15.7262
– volume: 25
  start-page: 1219
  issue: 10
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib117
  article-title: Role of thiol reactivity for targeting mutant p53
  publication-title: Cell Chem. Biol.
  doi: 10.1016/j.chembiol.2018.06.013
– volume: 10
  start-page: 548
  issue: 4
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib52
  article-title: The status of p53 oligomeric and aggregation states in cancer
  publication-title: Biomolecules
  doi: 10.3390/biom10040548
– volume: 125
  start-page: 407
  issue: 2
  year: 2011
  ident: 10.1016/j.heliyon.2024.e26260_bib129
  article-title: Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-010-0851-x
– volume: 72
  start-page: 102230
  year: 2023
  ident: 10.1016/j.heliyon.2024.e26260_bib36
  article-title: Inhibition of p53 protein aggregation as a cancer treatment strategy
  publication-title: Curr. Opin. Chem. Biol.
  doi: 10.1016/j.cbpa.2022.102230
– volume: 13
  start-page: 269
  issue: 2
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib67
  article-title: p53, A victim of the prion fashion
  publication-title: Cancers
  doi: 10.3390/cancers13020269
– volume: 9
  start-page: 439
  issue: 5
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib123
  article-title: APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-018-0463-7
– volume: 197
  start-page: 857
  issue: 7
  year: 2012
  ident: 10.1016/j.heliyon.2024.e26260_bib25
  article-title: The impact of the unfolded protein response on human disease
  publication-title: J. Cell Biol.
  doi: 10.1083/jcb.201110131
– volume: 9
  start-page: 402
  issue: 5
  year: 2008
  ident: 10.1016/j.heliyon.2024.e26260_bib33
  article-title: Transcriptional control of human p53-regulated genes
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/nrm2395
– volume: 162
  start-page: 452
  issue: 2
  year: 1988
  ident: 10.1016/j.heliyon.2024.e26260_bib78
  article-title: Evidence that immunological variants of p53 represent alternative protein conformation
  publication-title: Virology
  doi: 10.1016/0042-6822(88)90486-2
– volume: 7
  start-page: 41363
  issue: 27
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib135
  article-title: COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.9133
– volume: 81
  start-page: 2507
  issue: 12
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib26
  article-title: Maintenance of organellar protein homeostasis by ER-associated degradation and related mechanisms
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2021.05.004
– volume: 36
  start-page: 5473
  issue: 39
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib153
  article-title: Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp
  publication-title: Oncogene
  doi: 10.1038/onc.2017.152
– volume: 170
  start-page: 1062
  issue: 6
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib10
  article-title: Putting p53 in context
  publication-title: Cell
  doi: 10.1016/j.cell.2017.08.028
– year: 2019
  ident: 10.1016/j.heliyon.2024.e26260_bib166
– volume: 37
  start-page: 865
  issue: 9
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib50
  article-title: TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data
  publication-title: Hum. Mutat.
  doi: 10.1002/humu.23035
– volume: 7
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib173
  article-title: Therapeutic applications of CRISPR/Cas9 in breast cancer and delivery potential of gold nanomaterials
  publication-title: Nanobiomedicine (Rij)
– volume: 14
  start-page: 1215995
  year: 2023
  ident: 10.1016/j.heliyon.2024.e26260_bib113
  article-title: Targeting mutant p53 stabilization for cancer therapy
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2023.1215995
– volume: 352
  start-page: 77
  issue: 6330
  year: 1991
  ident: 10.1016/j.heliyon.2024.e26260_bib191
  article-title: Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
  publication-title: Nature
  doi: 10.1038/352077a0
– volume: 6
  start-page: 78
  issue: 1
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib193
  article-title: Epidermolysis bullosa
  publication-title: Nat. Rev. Dis. Prim.
  doi: 10.1038/s41572-020-0210-0
– volume: 33
  issue: 4
  year: 2013
  ident: 10.1016/j.heliyon.2024.e26260_bib88
  article-title: Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor
  publication-title: Biosci. Rep.
  doi: 10.1042/BSR20130065
– volume: 35
  start-page: 1334
  issue: 4
  year: 2014
  ident: 10.1016/j.heliyon.2024.e26260_bib168
  article-title: A cationic cholesterol based nanocarrier for the delivery of p53-EGFP-C3 plasmid to cancer cells
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2013.10.062
– volume: 428
  start-page: 319
  issue: 6980
  year: 2004
  ident: 10.1016/j.heliyon.2024.e26260_bib62
  article-title: Protein-only transmission of three yeast prion strains
  publication-title: Nature
  doi: 10.1038/nature02391
– volume: 33
  start-page: 527
  issue: 7
  year: 2013
  ident: 10.1016/j.heliyon.2024.e26260_bib46
  article-title: The effect of zinc and the role of p53 in copper-induced cellular stress responses
  publication-title: J. Appl. Toxicol.
  doi: 10.1002/jat.2854
– volume: 23
  start-page: 101
  issue: 1
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib169
  article-title: p53 gene therapy of human breast carcinoma: using a transferrin-modified silica nanoparticles
  publication-title: Breast Cancer
  doi: 10.1007/s12282-014-0537-z
– volume: 11
  start-page: 460
  issue: 6
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib160
  article-title: Mitochondrial dysfunction generates aggregates that resist lysosomal degradation in human breast cancer cells
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-020-2658-y
– volume: 9
  start-page: 3267
  issue: 1
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib150
  article-title: Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-05763-8
– volume: 170
  start-page: 213
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib20
  article-title: Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-018-4753-7
– volume: 55
  start-page: 98
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib128
  article-title: p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2015.12.002
– volume: 162
  start-page: 1365
  issue: 6
  year: 2010
  ident: 10.1016/j.heliyon.2024.e26260_bib192
  article-title: Identification of novel and known KRT5 and KRT14 mutations in 53 patients with epidermolysis bullosa simplex: correlation between genotype and phenotype
  publication-title: Br. J. Dermatol.
  doi: 10.1111/j.1365-2133.2010.09657.x
– volume: 37
  start-page: 174
  issue: 2
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib183
  article-title: Creutzfeldt‐jakob disease
  publication-title: Neuropathology
  doi: 10.1111/neup.12355
– volume: 5
  start-page: 8879
  issue: 19
  year: 2014
  ident: 10.1016/j.heliyon.2024.e26260_bib45
  article-title: Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2432
– volume: 10
  start-page: 288
  issue: 9
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib49
  article-title: p53 isoforms and their implications in cancer
  publication-title: Cancers
  doi: 10.3390/cancers10090288
– volume: 414
  start-page: 99
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib133
  article-title: Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigation with the anti-p53 drug, PK11007
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2017.09.053
– year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib8
  article-title: Specific degradation of misfolded mutant p53 in cancer cells through the use of natural compounds targeting mutant p53 and DNAJA1 proteins
– volume: 20
  start-page: 1226
  issue: 12
  year: 2019
  ident: 10.1016/j.heliyon.2024.e26260_bib57
  article-title: Protein misfolding diseases and therapeutic approaches
  publication-title: Curr. Protein Pept. Sci.
  doi: 10.2174/1389203720666190610092840
– volume: 8
  start-page: 75
  issue: 1
  year: 2014
  ident: 10.1016/j.heliyon.2024.e26260_bib99
  article-title: The aggregation of mutant p53 produces prion-like properties in cancer
  publication-title: Prion
  doi: 10.4161/pri.27776
– volume: vol. 79
  start-page: 58
  year: 2022
  ident: 10.1016/j.heliyon.2024.e26260_bib44
– volume: 278
  start-page: 24108
  issue: 26
  year: 2003
  ident: 10.1016/j.heliyon.2024.e26260_bib120
  article-title: Kinetic instability of p53 core domain mutants: implications for rescue by small molecules
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M302458200
– volume: 29
  start-page: 938
  issue: 5
  year: 2022
  ident: 10.1016/j.heliyon.2024.e26260_bib28
  article-title: The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein
  publication-title: Cell Death Differ.
  doi: 10.1038/s41418-022-00980-7
– volume: 20
  start-page: 146
  issue: 3
  year: 2004
  ident: 10.1016/j.heliyon.2024.e26260_bib184
  article-title: Huntingtin-protein interactions and the pathogenesis of Huntington's disease
  publication-title: Trends Genet.
  doi: 10.1016/j.tig.2004.01.008
– volume: 9
  start-page: 172
  issue: 12
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib127
  article-title: PRIMA-1 and PRIMA-1Met (APR-246): from mutant/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies
  publication-title: Cancers
  doi: 10.3390/cancers9120172
– volume: 21
  start-page: 71
  issue: 2
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib21
  article-title: Endoplasmic reticulum stress signals in the tumour and its microenvironment
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-020-00312-2
– volume: 15
  start-page: 657
  issue: 3
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib139
  article-title: Targeting cavity-creating p53 cancer mutations with small-molecule stabilizers: the Y220X paradigm
  publication-title: ACS Chem. Biol.
  doi: 10.1021/acschembio.9b00748
– volume: 14
  start-page: 157
  issue: 1
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib9
  article-title: Targeting mutant p53 for cancer therapy: direct and indirect strategies
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-021-01169-0
– volume: 20
  start-page: 199
  issue: 4
  year: 2019
  ident: 10.1016/j.heliyon.2024.e26260_bib30
  article-title: The multiple mechanisms that regulate p53 activity and cell fate
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/s41580-019-0110-x
– volume: 26
  start-page: 301
  issue: 3
  year: 2022
  ident: 10.1016/j.heliyon.2024.e26260_bib180
  article-title: Hyperactivating p53 in human papillomavirus-driven cancers: a potential therapeutic intervention
  publication-title: Mol. Diagn. Ther.
  doi: 10.1007/s40291-022-00583-5
– volume: 140
  start-page: 234
  issue: 1
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib19
  article-title: Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.30425
– start-page: 2930
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib94
  article-title: Dual modulators of p53 and Cyclin D in ER alpha signaling by albumin nanovectors bearing zinc chaperones for ER positive breast cancer therapy
  publication-title: Mini Rev. Med. Chem.
– volume: 32
  start-page: 72
  issue: 1
  year: 2013
  ident: 10.1016/j.heliyon.2024.e26260_bib107
  article-title: A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/1756-9966-32-72
– volume: 33
  start-page: 132
  issue: 3
  year: 2008
  ident: 10.1016/j.heliyon.2024.e26260_bib86
  article-title: Intriguing nucleic-acid-binding features of mammalian prion protein
  publication-title: Trends Biochem. Sci.
  doi: 10.1016/j.tibs.2007.11.003
– volume: 290
  start-page: 29769
  issue: 50
  year: 2015
  ident: 10.1016/j.heliyon.2024.e26260_bib147
  article-title: Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M115.690172
– volume: 109
  start-page: 13584
  issue: 34
  year: 2012
  ident: 10.1016/j.heliyon.2024.e26260_bib89
  article-title: Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1211550109
– volume: 6
  start-page: 55
  issue: 3
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib186
  article-title: Oxidative alterations in sickle cell disease: possible involvement in disease pathogenesis
  publication-title: World J. Hematol.
  doi: 10.5315/wjh.v6.i3.55
– volume: 24
  start-page: 927
  issue: 7
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib176
  article-title: CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0049-z
– volume: 277
  start-page: 228
  issue: 5323
  year: 1997
  ident: 10.1016/j.heliyon.2024.e26260_bib200
  article-title: Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis
  publication-title: Science
  doi: 10.1126/science.277.5323.228
– volume: 605
  start-page: 304
  issue: 7909
  year: 2022
  ident: 10.1016/j.heliyon.2024.e26260_bib55
  article-title: Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43
  publication-title: Nature
  doi: 10.1038/s41586-022-04670-9
– volume: 23
  start-page: 4883
  issue: 9
  year: 2022
  ident: 10.1016/j.heliyon.2024.e26260_bib187
  article-title: Retinitis pigmentosa: progress in molecular pathology and biotherapeutical strategies
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms23094883
– volume: 14
  issue: 17
  year: 2022
  ident: 10.1016/j.heliyon.2024.e26260_bib114
  article-title: Mutant p53 depletion by novel inhibitors for HSP40/J-domain proteins derived from the natural compound plumbagin
  publication-title: Cancers
  doi: 10.3390/cancers14174187
– volume: 39
  start-page: 260
  issue: 6
  year: 2014
  ident: 10.1016/j.heliyon.2024.e26260_bib13
  article-title: Prion-like aggregation of mutant p53 in cancer
  publication-title: Trends Biochem. Sci.
  doi: 10.1016/j.tibs.2014.04.001
– volume: 110
  start-page: E3445
  issue: 36
  year: 2013
  ident: 10.1016/j.heliyon.2024.e26260_bib155
  article-title: Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1303002110
– volume: 77
  start-page: 251
  issue: 2
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib71
  article-title: A non-amyloid prion particle that activates a heritable gene expression program
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2019.10.028
– volume: 10
  start-page: 5382
  issue: 1
  year: 2019
  ident: 10.1016/j.heliyon.2024.e26260_bib164
  article-title: Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-13305-z
– volume: 10
  start-page: 303
  issue: 2
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib103
  article-title: Follow the mutations: toward class-specific, small-molecule reactivation of p53
  publication-title: Biomolecules
  doi: 10.3390/biom10020303
– volume: 533
  start-page: 420
  issue: 7603
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib175
  article-title: Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
  publication-title: Nature
  doi: 10.1038/nature17946
– volume: 86
  start-page: 27
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib60
  article-title: Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade
  publication-title: Annu. Rev. Biochem.
  doi: 10.1146/annurev-biochem-061516-045115
– volume: 24
  start-page: 73
  issue: 1
  year: 2010
  ident: 10.1016/j.heliyon.2024.e26260_bib95
  article-title: Implication of necrosis-linked p53 aggregation in acquired apoptotic resistance to 5-FU in MCF-7 multicellular tumour spheroids
  publication-title: Oncol. Rep.
– volume: 13
  start-page: 3676
  issue: 5
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib179
  article-title: Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: a clinical trial
  publication-title: Oncol. Lett.
  doi: 10.3892/ol.2017.5901
– volume: 11
  start-page: 19264
  issue: 1
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib136
  article-title: Pathogenic genetic variants from highly connected cancer susceptibility genes confer the loss of structural stability
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-021-98547-y
– volume: 42
  start-page: 9679
  issue: 26
  year: 2013
  ident: 10.1016/j.heliyon.2024.e26260_bib106
  article-title: Improving the bioactivity of Zn(II)-curcumin based complexes
  publication-title: Dalton Trans.
  doi: 10.1039/c3dt50513h
– volume: 92
  start-page: 4407
  issue: 10
  year: 1995
  ident: 10.1016/j.heliyon.2024.e26260_bib75
  article-title: Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.92.10.4407
– volume: 71
  start-page: 19
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib6
  article-title: Restoring guardianship of the genome: anticancer drug strategies to reverse oncogenic mutant p53 misfolding
  publication-title: Cancer Treat Rev.
  doi: 10.1016/j.ctrv.2018.09.004
– volume: 46
  start-page: 6471
  issue: 6
  year: 2019
  ident: 10.1016/j.heliyon.2024.e26260_bib174
  article-title: Evaluation of the CRISPR/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3
  publication-title: Mol. Biol. Rep.
  doi: 10.1007/s11033-019-05093-y
– volume: 14
  start-page: 2850
  issue: 12
  year: 2015
  ident: 10.1016/j.heliyon.2024.e26260_bib143
  article-title: Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator nutlin-3a in a humanized orthotopic breast-to-lung metastatic ModelModulation of Mdm2 in the context of DNA damage
  publication-title: Mol. Cancer Therapeut.
  doi: 10.1158/1535-7163.MCT-15-0237
– volume: 15
  start-page: 384
  issue: 6
  year: 2014
  ident: 10.1016/j.heliyon.2024.e26260_bib61
  article-title: The amyloid state and its association with protein misfolding diseases
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/nrm3810
– volume: 71
  start-page: 178
  issue: 1
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib41
  article-title: A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2018.06.012
– volume: 462
  start-page: 293
  issue: 2–3
  year: 2000
  ident: 10.1016/j.heliyon.2024.e26260_bib70
  article-title: The yeast p53 functional assay: a new tool for molecular epidemiology. Hopes and facts
  publication-title: Mutat. Res.
  doi: 10.1016/S1383-5742(00)00011-9
– volume: 428
  start-page: 323
  issue: 6980
  year: 2004
  ident: 10.1016/j.heliyon.2024.e26260_bib63
  article-title: Conformational variations in an infectious protein determine prion strain differences
  publication-title: Nature
  doi: 10.1038/nature02392
– volume: 83
  start-page: 258
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib101
  article-title: Mutant p53 as a target for cancer treatment
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2017.06.023
– volume: 13
  start-page: 3496
  issue: 15
  year: 1994
  ident: 10.1016/j.heliyon.2024.e26260_bib77
  article-title: Analysis of the most representative tumour‐derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation
  publication-title: EMBO J.
  doi: 10.1002/j.1460-2075.1994.tb06656.x
– volume: 26
  start-page: 1268
  issue: 12
  year: 2012
  ident: 10.1016/j.heliyon.2024.e26260_bib43
  article-title: Mutant p53: one name, many proteins
  publication-title: Genes Dev.
  doi: 10.1101/gad.190678.112
– volume: 22
  start-page: 61
  issue: 1
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib5
  article-title: Triple-negative breast cancer molecular subtyping and treatment progress
  publication-title: Breast Cancer Res.
  doi: 10.1186/s13058-020-01296-5
– volume: 294
  start-page: 3670
  issue: 10
  year: 2019
  ident: 10.1016/j.heliyon.2024.e26260_bib122
  article-title: p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA118.004671
– start-page: 2930
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib131
  article-title: Combined treatment using the anti-p53 drug, APR-246 and eribulin: synergistic growth inhibition in p53-mutated breast cancer cells
  publication-title: J. Clin. Oncol.
– volume: 11
  start-page: a033928
  issue: 8
  year: 2019
  ident: 10.1016/j.heliyon.2024.e26260_bib23
  article-title: Chaperoning endoplasmic reticulum-associated degradation (ERAD) and protein conformational diseases
  publication-title: Cold Spring Harbor Perspect. Biol.
  doi: 10.1101/cshperspect.a033928
– volume: 77
  start-page: 2699
  issue: 10
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib162
  article-title: Development of a T-cell receptor mimic antibody against wild-type p53 for cancer ImmunotherapyTCR mimic antibody against p53 for cancer immunotherapy
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-3247
– volume: 77
  start-page: 266
  issue: 2
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib72
  article-title: Widespread prion-based control of growth and differentiation strategies in Saccharomyces cerevisiae
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2019.10.027
– volume: 21
  start-page: 792
  issue: 7
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib110
  article-title: Dual modulators of p53 and Cyclin D in ER alpha signaling by albumin nanovectors bearing zinc chaperones for ER-positive breast cancer therapy
  publication-title: Mini Rev. Med. Chem.
  doi: 10.2174/1389557520999201124212347
– volume: 150
  year: 2019
  ident: 10.1016/j.heliyon.2024.e26260_bib69
  article-title: Yeast as a chassis for developing functional assays to study human P53
  publication-title: J. Vis. Exp.
– volume: 23
  start-page: 1615
  issue: 10
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib161
  article-title: Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth
  publication-title: Cell Death Differ.
  doi: 10.1038/cdd.2016.48
– volume: vol. 6
  start-page: 29
  year: 1995
  ident: 10.1016/j.heliyon.2024.e26260_bib196
– volume: 7
  start-page: 285
  issue: 5
  year: 2011
  ident: 10.1016/j.heliyon.2024.e26260_bib92
  article-title: Gain of function of mutant p53 by coaggregation with multiple tumor suppressors
  publication-title: Nat. Chem. Biol.
  doi: 10.1038/nchembio.546
– volume: 53
  start-page: 5995
  issue: 38
  year: 2014
  ident: 10.1016/j.heliyon.2024.e26260_bib116
  article-title: Investigating the intrinsic aggregation potential of evolutionarily conserved segments in p53
  publication-title: Biochemistry
  doi: 10.1021/bi500825d
– volume: 395
  start-page: 705
  issue: 4
  year: 2010
  ident: 10.1016/j.heliyon.2024.e26260_bib90
  article-title: Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function
  publication-title: J. Mol. Biol.
  doi: 10.1016/j.jmb.2009.11.013
– volume: 15
  start-page: 67
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib165
  article-title: The current status of gene therapy for the treatment of cancer
  publication-title: Biologics
– volume: 27
  start-page: 739
  issue: 4
  year: 1998
  ident: 10.1016/j.heliyon.2024.e26260_bib198
  article-title: Hypogonadotropic hypogonadism
  publication-title: Endocrinol Metab. Clin. N. Am.
  doi: 10.1016/S0889-8529(05)70039-6
– volume: 11
  start-page: 4436
  issue: 23
  year: 2012
  ident: 10.1016/j.heliyon.2024.e26260_bib157
  article-title: Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy
  publication-title: Cell Cycle
  doi: 10.4161/cc.22778
– volume: 5
  start-page: 289
  year: 2015
  ident: 10.1016/j.heliyon.2024.e26260_bib137
  article-title: Mutant p53: one, No one, and one hundred thousand
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2015.00289
– volume: 43
  start-page: 271
  issue: 2
  year: 2010
  ident: 10.1016/j.heliyon.2024.e26260_bib87
  article-title: Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins
  publication-title: Acc. Chem. Res.
  doi: 10.1021/ar900179t
– volume: 51
  start-page: 181
  issue: 1
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib15
  article-title: Targeting the prion-like aggregation of mutant p53 to combat cancer
  publication-title: Acc. Chem. Res.
  doi: 10.1021/acs.accounts.7b00473
– volume: 23
  start-page: 29
  issue: 1
  year: 2021
  ident: 10.1016/j.heliyon.2024.e26260_bib156
  article-title: First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
  publication-title: Breast Cancer Res.
  doi: 10.1186/s13058-021-01406-x
– volume: 59
  start-page: 146
  issue: 2
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib17
  article-title: Prion-like p53 amyloids in cancer
  publication-title: Biochemistry
  doi: 10.1021/acs.biochem.9b00796
– volume: 285
  start-page: 2857
  issue: 4
  year: 2010
  ident: 10.1016/j.heliyon.2024.e26260_bib58
  article-title: The p53 core domain is a molten globule at low pH: functional implications of a partially unfolded structure
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M109.075861
– volume: 20
  start-page: 49
  issue: 2
  year: 1995
  ident: 10.1016/j.heliyon.2024.e26260_bib65
  article-title: Flexibility: the key to p53 function?
  publication-title: Trends Biochem. Sci.
  doi: 10.1016/S0968-0004(00)88954-9
– volume: 1
  start-page: 321
  issue: 5
  year: 1992
  ident: 10.1016/j.heliyon.2024.e26260_bib190
  article-title: Mislocalization of ΔF508 CFTR in cystic fibrosis sweat gland
  publication-title: Nat. Genet.
  doi: 10.1038/ng0892-321
– volume: 68
  start-page: 6708
  issue: 16
  year: 2008
  ident: 10.1016/j.heliyon.2024.e26260_bib141
  article-title: Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-08-0349
– volume: 381
  start-page: 61
  issue: 1–2
  year: 2013
  ident: 10.1016/j.heliyon.2024.e26260_bib172
  article-title: p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells
  publication-title: Mol. Cell. Biochem.
  doi: 10.1007/s11010-013-1688-5
– volume: 10
  start-page: 188
  issue: 6
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib40
  article-title: Gain-of-function (GOF) mutant p53 as actionable therapeutic target
  publication-title: Cancers
  doi: 10.3390/cancers10060188
– volume: 113
  start-page: E5271
  issue: 36
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib132
  article-title: 2-Sulfonylpyrimidines: mild alkylating agents with anticancer activity toward p53-compromised cells
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1610421113
– volume: 18
  start-page: 1233
  issue: 11
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib112
  article-title: DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway
  publication-title: Nat. Cell Biol.
  doi: 10.1038/ncb3427
– volume: 22
  start-page: 127
  issue: 2
  year: 2023
  ident: 10.1016/j.heliyon.2024.e26260_bib163
  article-title: Drugging p53 in cancer: one protein, many targets
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-022-00571-8
– volume: 11
  start-page: 2581
  issue: 14
  year: 2012
  ident: 10.1016/j.heliyon.2024.e26260_bib7
  article-title: p53 reactivation: the link to zinc
  publication-title: Cell Cycle
  doi: 10.4161/cc.21020
– volume: 86
  start-page: 69
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib59
  article-title: Structural studies of amyloid proteins at the molecular level
  publication-title: Annu. Rev. Biochem.
  doi: 10.1146/annurev-biochem-061516-045104
– volume: 23
  start-page: 11023
  issue: 19
  year: 2022
  ident: 10.1016/j.heliyon.2024.e26260_bib98
  article-title: Anticancer therapeutic strategies targeting p53 aggregation
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms231911023
– volume: 11
  start-page: 330
  issue: 4
  year: 2019
  ident: 10.1016/j.heliyon.2024.e26260_bib37
  article-title: p53 as a hub in cellular redox regulation and therapeutic target in cancer
  publication-title: J. Mol. Cell Biol.
  doi: 10.1093/jmcb/mjz005
– volume: 21
  issue: 5
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib3
  article-title: Effect of CD44 aptamer on snail metastasis factor and aggressiveness of MDA-MB-231 breast cancer cell line
  publication-title: Shiraz E Med. J.
  doi: 10.5812/semj.94641
– volume: 148
  start-page: 1188
  issue: 6
  year: 2012
  ident: 10.1016/j.heliyon.2024.e26260_bib54
  article-title: The amyloid state of proteins in human diseases
  publication-title: Cell
  doi: 10.1016/j.cell.2012.02.022
– volume: 28
  start-page: 639
  issue: 8
  year: 2017
  ident: 10.1016/j.heliyon.2024.e26260_bib167
  article-title: Induction of oxidants distinguishes susceptibility of prostate carcinoma cell lines to p53 gene transfer mediated by an improved adenoviral vector
  publication-title: Hum. Gene Ther.
  doi: 10.1089/hum.2016.139
– volume: 25
  start-page: 215
  issue: 4
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib84
  article-title: Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee
  publication-title: Amyloid
  doi: 10.1080/13506129.2018.1549825
– volume: 30
  start-page: 384
  issue: 5
  year: 2020
  ident: 10.1016/j.heliyon.2024.e26260_bib22
  article-title: ER-phagy: quality control and turnover of endoplasmic reticulum
  publication-title: Trends Cell Biol.
  doi: 10.1016/j.tcb.2020.02.001
– volume: 29
  start-page: 160
  issue: 2
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib178
  article-title: The first approved gene therapy product for cancer ad-p53 (gendicine): 12 Years in the clinic
  publication-title: Hum. Gene Ther.
  doi: 10.1089/hum.2017.218
– volume: 86
  start-page: 109
  issue: 1
  year: 2008
  ident: 10.1016/j.heliyon.2024.e26260_bib185
  article-title: A review of Parkinson's disease
  publication-title: Br. Med. Bull.
  doi: 10.1093/bmb/ldn013
– volume: 7
  start-page: 69549
  issue: 43
  year: 2016
  ident: 10.1016/j.heliyon.2024.e26260_bib68
  article-title: The dominant-negative interplay between p53, p63 and p73: a family affair
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.11774
– volume: 18
  start-page: 89
  issue: 2
  year: 2018
  ident: 10.1016/j.heliyon.2024.e26260_bib102
  article-title: Targeting mutant p53 for efficient cancer therapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2017.109
– volume: 24
  start-page: 2206
  issue: 9
  year: 2013
  ident: 10.1016/j.heliyon.2024.e26260_bib4
  article-title: Personalizing the treatment of women with early breast cancer: highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2013
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdt303
– volume: 1
  start-page: 779
  issue: 7
  year: 2010
  ident: 10.1016/j.heliyon.2024.e26260_bib158
  article-title: The role of ubiquitin in autophagy-dependent protein aggregate processing
  publication-title: Genes Cancer
  doi: 10.1177/1947601910383277
SSID ssj0001586973
Score 2.2698371
SecondaryResourceType review_article
Snippet Breast cancer (BC) is viewed as a significant public health issue and is the primary cause of cancer-related deaths among women worldwide. Triple-negative...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e26260
SubjectTerms breast neoplasms
cancer therapy
Cancer treatment
CRISPR-Cas systems
DNA damage
epidemiology
immunotherapy
Mutant p53
mutants
pathogenesis
premenopause
Prion-like aggregation
public health
Review
Triple-negative breast cancer
Title Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions
URI https://dx.doi.org/10.1016/j.heliyon.2024.e26260
https://www.ncbi.nlm.nih.gov/pubmed/38390040
https://www.proquest.com/docview/3153847078
https://www.proquest.com/docview/3182879281
https://pubmed.ncbi.nlm.nih.gov/PMC10881377
https://doaj.org/article/d2b3aada06e44327b29bff0937937283
Volume 10
WOSCitedRecordID wos001187987600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: Directory of Open Access Journals
  customDbUrl:
  eissn: 2405-8440
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001586973
  issn: 2405-8440
  databaseCode: DOA
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2405-8440
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001586973
  issn: 2405-8440
  databaseCode: M~E
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWgQogL4pstUA0S12w3jjdxuAFqxaUVByrtLbIdu03ZJqski8Slv4YfykycLAlI7IXLHrL5sD3PnjeJ5w1j75xBThvHPFhoJQPhcKbL2ERByF0S5YtlnnLVFZtIzs_lapV-GZX6oj1hXh7YD9xxznWkVK4WsRUi4onmqXYO43ASdkPfSKsvsp5RMOXzg2WcJtHvlJ3j6_mVXRc_KtI85WJuOTH5iTPqNPsnPulvzvnn1smRLzp9xB72JBI--MY_Znds-YTdP-s_kz9lPy_GKSuAHA82NRogWBffLAyZ-VA5uNlSFWHYLCPoFBuKsoGihLam9-9BaS87XXDQtHW9BUMQqYGqGFeXtEgWzXtAoIHxKk8wyuaCph1UKADbAV68BLwLJaw_YxenJ18_fQ76cgyBWcZJGwiMo51QBmexS5HoYeSiQyQoxoWp05zL3KVamEQgKct54hYLtJ0KLYbBfKmRJj1nB2VV2pcMcpVbI6UQSa6FME65MLGxVlo6bvFeMyYGu2Sm1yqnkhnrbNiUdp315szInJk354zNd5dtvFjHvgs-ktF3J5PWdncAEZj1CMz2IXDG5ACZrKctfizxVsW-578dIJbhtKZvNaq01bbJIvJEgqSY_nUOVStIuQxn7IWH5a4nERJfWqCxcRPATro6_acsrjp58RAdD-lQHv6PwXnFHlB_OxGA9DU7aOutfcPume9t0dRH7G6ykkfd1MXfs9uTX4aOTyY
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Understanding+the+prion-like+behavior+of+mutant+p53+proteins+in+triple-negative+breast+cancer+pathogenesis%3A+The+current+therapeutic+strategies+and+future+directions&rft.jtitle=Heliyon&rft.au=Naeimzadeh%2C+Yasaman&rft.au=Tajbakhsh%2C+Amir&rft.au=Fallahi%2C+Jafar&rft.date=2024-02-29&rft.issn=2405-8440&rft.eissn=2405-8440&rft.volume=10&rft.issue=4&rft.spage=e26260&rft_id=info:doi/10.1016%2Fj.heliyon.2024.e26260&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_heliyon_2024_e26260
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2405-8440&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2405-8440&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2405-8440&client=summon